# Washington University

**Report on Federal Financial Assistance Programs in Accordance with Uniform Guidance**
**For the Year Ended June 30, 2024**
**Employer Identification Number: 43-0653611**

# Washington University
## Report on Federal Financial Assistance Programs in Accordance with Uniform Guidance
## Index
## June 30, 2024


**Page(s)**

A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION

Report of Independent Auditors ..... 1–3

Consolidated Financial Statements for the Years Ended June 30, 2024 and 2023.....4–34

Schedule of Expenditures of Federal Awards ..... 35–52

Notes to Schedule of Expenditures of Federal Awards ..... 53

B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards .....54–55

Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance ..... 56–58

C. SCHEDULE OF FINDINGS AND QUESTIONED COSTS

Part I – Summary of Auditors' Results ..... 59

Part II – Financial Statement Findings ..... 60

Part III – Federal Award Findings and Questioned Costs ..... 60–63

Management's Views and Corrective Action Plan ..... 64–66

D. SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS

Part IV – Summary of Status of Prior Audit Findings .....67

# Financial Statements and Supplemental Information

## Report of Independent Auditors

To the Board of Trustees of Washington University

### Report on the Audit of the Consolidated Financial Statements

#### *Opinion*

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statements of financial position as of June 30, 2024 and 2023, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of June 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### *Basis for Opinion*

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### *Responsibilities of Management for the Consolidated Financial Statements*

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

#### *Auditors' Responsibilities for the Audit of the Consolidated Financial Statements*

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from

fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

***Supplemental Information***

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2024 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

**Other Reporting Required by Government Auditing Standards**

In accordance with Government Auditing Standards, we have also issued our report dated September 27, 2024 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2024. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the University's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Washington, District of Columbia

September 27, 2024

# Washington University
## Consolidated Statements of Financial Position
## June 30, 2024 and 2023

| *(thousands of dollars)* | 2024 | 2023 |
|---|---|---|
| **Assets** | | |
| Cash and cash equivalents | $ 230,474 | $ 316,820 |
| Investments | 14,697,939 | 14,311,571 |
| Accounts and notes receivable, net | 836,930 | 723,215 |
| Pledges receivable, net | 405,133 | 418,821 |
| Right-of-use assets | 88,882 | 93,447 |
| Other assets | 433,132 | 362,291 |
| Fixed assets, net | 3,794,317 | 3,566,162 |
| Total assets | $ 20,486,807 | $ 19,792,327 |
| **Liabilities** | | |
| Accounts payable and accrued expenses | $ 741,620 | $ 731,057 |
| Deposits, advances and other | 35,654 | 48,541 |
| Lease liability | 98,715 | 104,087 |
| Professional liability | 113,686 | 104,012 |
| Deferred revenue and contract liabilities | 141,837 | 124,803 |
| Liabilities under split-interest agreements | 33,691 | 34,607 |
| Notes and bonds payable | 3,266,308 | 3,259,475 |
| Total liabilities | 4,431,511 | 4,406,582 |
| **Net Assets** | | |
| Without donor restrictions | 8,004,693 | 7,693,793 |
| With donor restrictions | 8,050,603 | 7,691,952 |
| Total net assets | 16,055,296 | 15,385,745 |
| Total liabilities and net assets | $ 20,486,807 | $ 19,792,327 |

The accompanying notes are an integral part of these consolidated financial statements.

# Washington University
## Consolidated Statements of Activities
## Year Ended June 30, 2024

| *(thousands of dollars)* | Without Donor Restrictions | With Donor Restrictions | Total |
|---|---|---|---|
| **Revenues and other support** | | | |
| Tuition and fees | $ 479,327 | $ - | $ 479,327 |
| Endowment spending distribution | 553,240 | 22,705 | 575,945 |
| Investment income | 94,241 | 777 | 95,018 |
| Gifts | 107,570 | 139,686 | 247,256 |
| Grants and contracts revenues | | | |
| Direct costs recovered | 671,148 | - | 671,148 |
| Facilities and administrative costs recovered | 256,425 | - | 256,425 |
| Patient services, net | 2,359,708 | - | 2,359,708 |
| Auxiliary enterprises - sales and services | 142,534 | - | 142,534 |
| Educational activities - sales and services | 170,455 | - | 170,455 |
| Affiliated hospital revenues | 189,804 | - | 189,804 |
| Other revenue | 45,854 | 2 | 45,856 |
| Net assets released from restrictions | 140,290 | (140,290) | - |
| Total revenues and other support | 5,210,596 | 22,880 | 5,233,476 |
| **Expenses** | | | |
| Compensation expense | 3,079,115 | - | 3,079,115 |
| Supplies, services, and other | 1,643,736 | - | 1,643,736 |
| Depreciation expense | 255,521 | - | 255,521 |
| Interest expense | 104,787 | - | 104,787 |
| Total expenses | 5,083,159 | - | 5,083,159 |
| Net operating results | 127,437 | 22,880 | 150,317 |
| **Non-operating activities** | | | |
| Investment returns net of endowment spending | 210,616 | 236,330 | 446,946 |
| Permanently restricted gifts | - | 78,708 | 78,708 |
| Other non-operating | (27,153) | 20,733 | (6,420) |
| Non-operating, net | 183,463 | 335,771 | 519,234 |
| Change in net assets | 310,900 | 358,651 | 669,551 |
| Net Assets, Beginning of the Year | 7,693,793 | 7,691,952 | 15,385,745 |
| Net Assets, End of the Year | $ 8,004,693 | $ 8,050,603 | $ 16,055,296 |

The accompanying notes are an integral part of these consolidated financial statements.

# Washington University
## Consolidated Statements of Activities
## Year Ended June 30, 2023

| *(thousands of dollars)* | Without Donor Restrictions | With Donor Restrictions | Total |
|---|---|---|---|
| **Revenues and other support** | | | |
| Tuition and fees | $ 497,365 | $ - | $ 497,365 |
| Endowment spending distribution | 552,477 | 17,312 | 569,789 |
| Investment income | 71,397 | 837 | 72,234 |
| Gifts | 110,294 | 93,854 | 204,148 |
| Grants and contracts revenues | | | |
| Direct costs recovered | 617,177 | - | 617,177 |
| Facilities and administrative costs recovered | 235,870 | - | 235,870 |
| Patient services, net | 2,052,095 | - | 2,052,095 |
| Auxiliary enterprises - sales and services | 137,124 | - | 137,124 |
| Educational activities - sales and services | 168,263 | - | 168,263 |
| Affiliated hospital revenues | 164,808 | - | 164,808 |
| Other revenue | 38,130 | - | 38,130 |
| Net assets released from restrictions | 122,374 | (122,374) | - |
| Total revenues and other support | 4,767,374 | (10,371) | 4,757,003 |
| **Expenses** | | | |
| Compensation expense | 2,770,311 | - | 2,770,311 |
| Supplies, services, and other | 1,481,509 | - | 1,481,509 |
| Depreciation expense | 224,969 | - | 224,969 |
| Interest expense | 93,738 | - | 93,738 |
| Total expenses | 4,570,527 | - | 4,570,527 |
| Net operating results | 196,847 | (10,371) | 186,476 |
| **Non-operating activities** | | | |
| Investment returns net of endowment spending | (343,688) | (593,435) | (937,123) |
| Permanently restricted gifts | - | 88,345 | 88,345 |
| Other non-operating | (6,454) | 10,047 | 3,593 |
| Non-operating, net | (350,142) | (495,043) | (845,185) |
| Change in net assets | (153,295) | (505,414) | (658,709) |
| Net Assets, Beginning of the Year | 7,847,088 | 8,197,366 | 16,044,454 |
| Net Assets, End of the Year | $ 7,693,793 | $ 7,691,952 | $ 15,385,745 |

The accompanying notes are an integral part of these consolidated financial statements.

# Washington University
## Consolidated Statements of Cash Flows
## Years Ended June 30, 2024 and 2023

| *(thousands of dollars)* | 2024 | 2023 |
|---|---|---|
| **Cash flows from operating activities** | | |
| Change in net assets | $ 669,551 | $ (658,709) |
| Adjustments to reconcile change in net assets to cash used in operating activities | | |
| Realized and unrealized net (gains) and losses on investments | (1,073,305) | 313,738 |
| Depreciation expense | 255,521 | 224,969 |
| Permanently restricted gifts | (78,708) | (88,345) |
| Investments received as gifts - not permanently restricted | (38,204) | (5,193) |
| Proceeds from sales of investments received as gifts | 38,204 | 5,193 |
| Other non-cash adjustments | 3,440 | 39,135 |
| Changes in assets and liabilities | | |
| Accounts and notes receivable, net | (98,487) | 15,183 |
| Pledges receivable, net | 11,008 | 1,668 |
| Accounts payable and accrued expenses | (14,710) | 24,374 |
| Deferred revenue and contract liabilities | 17,034 | (5,677) |
| Lease liabilities | (23,753) | (22,635) |
| Other assets and liabilities | (31,869) | (41,611) |
| Net cash used by operating activities | (364,278) | (197,910) |
| **Cash flows from investing activities** | | |
| Proceeds from sales and maturities of investments | 4,048,801 | 7,625,584 |
| Purchases of investments | (3,350,448) | (6,831,465) |
| Purchases of fixed assets | (510,219) | (543,043) |
| Student loans disbursed | (16,189) | (16,987) |
| Student loan payments received | 14,609 | 15,956 |
| Other | (22) | (288) |
| Net cash provided by investing activities | 186,532 | 249,757 |
| **Cash flows from financing activities** | | |
| Principal payments of debt | (2,577) | (79,942) |
| Proceeds from long-term debt issuance | 8,930 | 14,340 |
| Contributions restricted for long-term investment | 72,117 | 67,097 |
| Proceeds from sales of investments received as permanently restricted gifts | 12,930 | 24,287 |
| Net cash provided by financing activities | 91,400 | 25,782 |
| Net (decrease)/increase in cash and cash equivalents | (86,346) | 77,629 |
| **Cash and cash equivalents** | | |
| Beginning of year | 316,820 | 239,191 |
| End of year | $ 230,474 | $ 316,820 |
| **Supplemental data** | | |
| Interest paid in cash | $ 103,379 | $ 92,785 |
| **Noncash activities** | | |
| Contributions of securities and other noncash assets | (51,134) | (29,480) |
| Right-of-use assets obtained in exchange for lease liabilities | (20,805) | (26,921) |
| Net change in accounts payable for fixed assets | (16,889) | 19,644 |
| Net change in accounts receivable for investments | (14,096) | (16,197) |
| Net change in accounts payable for investments | 4,287 | 14,530 |

The accompanying notes are an integral part of these consolidated financial statements.

*(All amounts in thousands of dollars)*

## 1. Summary of Significant Accounting Policies

### Organization

Washington University in St. Louis (the "university") is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

### Basis of Presentation and Use of Estimates

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates. Significant consolidated affiliates include The Barnard Free Skin and Cancer Hospital, Quadrangle Management Company, Parallel Properties LLC including its affiliates, Washington University Clinical Associates, LLC and associated physician practices, and Washington University Physicians in Illinois, Inc.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for contractual adjustments and doubtful accounts. Actual results could differ from those estimates.

Certain reclassifications have been made to the 2023 financial statements to conform to the 2024 financial statement presentation. These reclassifications had no effect on changes in net assets.

### Net Assets

Resources are recorded based on the absence or existence of donor-imposed restrictions. Descriptions of the net asset categories are as follows:

- Net assets without donor restrictions are free of donor-imposed restrictions. Board-designated endowment funds are also included within net assets without donor restrictions.

- Net assets with donor restrictions represent net assets that consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time as well as gifts and trusts which, by donor restriction, are required to be held in perpetuity. Net assets required to be held in perpetuity at June 30, 2024 and 2023, are $2,725,313 and $2,638,879, respectively.

Revenues from sources other than contributions and investment returns are reported as increases in net assets without donor restrictions. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose donor

restrictions that are met in the same fiscal year they are received are included in revenues without donor restrictions. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted endowments. Such amounts, reported in the non-operating section of the consolidated statement of activities, remain in net assets with donor restrictions until appropriated for expenditure. When a donor restriction expires due to the passage of time or the university's fulfillment of donor stipulated purpose, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions. Donor restricted gifts that are to be held in perpetuity are reported in the non-operating section of the consolidated statements of activities. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in net assets without donor restrictions.

The university's net assets as of June 30, 2024 consist of the following:

| | Without donor restrictions | With donor restrictions | Total |
|---|---|---|---|
| Donor-restricted endowment funds | $ - | $ 6,991,404 | $ 6,991,404 |
| Board-designated endowment funds | 4,439,294 | 575,328 | 5,014,622 |
| Investment in plant, net | 848,876 | - | 848,876 |
| Pledges | - | 405,133 | 405,133 |
| Other donor-restricted | - | 78,738 | 78,738 |
| Operating and other reserves | 2,716,523 | - | 2,716,523 |
| | $ 8,004,693 | $ 8,050,603 | $ 16,055,296 |

The university's net assets as of June 30, 2023 consist of the following:

| | Without donor restrictions | With donor restrictions | Total |
|---|---|---|---|
| Donor-restricted endowment funds | $ - | $ 6,686,908 | $ 6,686,908 |
| Board-designated endowment funds | 4,279,133 | 523,273 | 4,802,406 |
| Investment in plant, net | 884,026 | - | 884,026 |
| Pledges | - | 418,821 | 418,821 |
| Other donor-restricted | - | 62,950 | 62,950 |
| Operating and other reserves | 2,530,634 | - | 2,530,634 |
| | $ 7,693,793 | $ 7,691,952 | $ 15,385,745 |

*(All amounts in thousands of dollars)*

### Cash and Cash Equivalents

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as short-term investments, to be cash and cash equivalents.

### Investments

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the consolidated statements of activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

At June 30, 2024 and 2023, investments include $320,867 and $577,339, respectively, purchased with unexpended proceeds from the Series 2020A Missouri Health and Educational Facilities Authority (MOHEFA) taxable revenue bonds issued April 3, 2020 and the Series 2022 taxable bonds issued April 7, 2022. The 2020A MOHEFA funds and the 2022 bond funds may be utilized for the purposes set forth in the relevant bond documents.

### Financing Receivables

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins Student Loan program. Loan funds are reported at estimated realizable value, which approximates fair value. Federal funds are ultimately refundable to the government and are recognized as a liability in the consolidated statements of financial position.

The university's loan portfolio includes over 3,400 individual loans and is geographically diverse. Loans are considered past due if the minimum payment is not received within ten days past the due date. At June 30, 2024 and 2023, respectively 93% and 94% of the parent loans and 78% and 76% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

### Other Assets

Other assets primarily consist of prepaid expenses, deposits, inventories, and deferred compensation. The university offers deferred compensation plans for eligible faculty and staff. The plans investments are recorded at market value in other assets with an offsetting liability recorded in accounts payable and accrued expenses within the consolidated statement of financial position.

### Leases

The university determines if an arrangement is or contains a lease at inception based on whether the contract conveys the right to control the use of identified property, plant, or equipment in exchange for consideration. The university has both leases under which it is obligated as a lessee and leases for which it is the lessor. Operating leases in which the university is a lessee are included in right-of-use (ROU) assets and lease liabilities on the consolidated statements of financial position. The university has elected the short-term lease exception under ASC 842 for all leases, and therefore, leases with an initial term of 12 months

or less are not included on the consolidated statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The interest rate implicit in lease contracts is typically not readily determinable, and as such, the university uses its collateralized borrowing rate using a period comparable with the lease term in determining the present value of lease payments. The lease term may, at the university's discretion, include options to extend or to terminate the lease that the university is reasonably certain to exercise. Lease expense for lease payments is recognized on a straight-line basis over the lease term within the supplies, services and other line of the consolidated statement of activities. Variable lease payments based on an index or rate, such as the consumer price index, are initially measured using the index or rate in effect at lease commencement. The university has lease agreements with non-lease components that relate to the lease components. The university elected the practical expedient to account for non-lease components and the lease components to which they relate as a single lease component for all leases. Leasing arrangements for which the university is the lessor are not material to the consolidated financial statements.

**Fixed Assets**

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation. Depreciation is calculated using the straight-line method with estimated useful lives of 10-to-50 years for buildings and building improvements, and 3-to-20 years for equipment, depending upon asset class. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Fixed assets by classification at June 30, 2024 and 2023 consist of the following:

| | 2024 | 2023 |
|---|---|---|
| Construction in progress | $ 605,303 | $ 911,778 |
| Land and improvements to land | 245,591 | 219,694 |
| Buildings | 5,635,423 | 4,944,844 |
| Equipment | 857,756 | 820,403 |
| Total cost | 7,344,073 | 6,896,719 |
| Accumulated depreciation | (3,549,756) | (3,330,557) |
| Total fixed assets, net | $ 3,794,317 | $ 3,566,162 |

**Collections**

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. Proceeds from the sale of deaccessioned items are used to acquire new collections. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

*(All amounts in thousands of dollars)*

### Deferred Revenue and Contract Liabilities

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are grants and contracts and prepaid tuition and housing.

### Split-Interest Agreements

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is the standard IRS discount rate in existence at the date of the gift. The rates used range from 4.6% to 5.8% for 2024 and 1.4% to 5.0% for fiscal year 2023. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries.

### Tuition and Fees

Tuition and fee revenue, net of scholarships and other implicit price concessions, is recognized over-time using the output method of measuring progress in the fiscal year in which the educational programs are conducted. Students are invoiced at the commencement of each academic period. Payment is due when invoiced. The performance obligation, delivery of educational services, is satisfied as services are rendered. If delivery of the performance obligation is not complete as of fiscal year-end, a contractual liability is recorded. The deferred contract liability at June 30, 2024 and 2023 was $40,535 and $43,286, respectively, and is reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to students by the university, including aid provided to employees and their dependents, for the years ended June 30, 2024 and 2023, respectively, was $507,861 and $477,070.

The table below identifies student aid by type. Scholarships are reported net against tuition in the consolidated statements of activities. Other amounts are reported as expenses.

*(All amounts in thousands of dollars)*

| | 2024 | 2023 |
|---|---|---|
| Scholarships from unrestricted sources | $ 250,253 | $ 239,871 |
| Scholarship support from gifts, endowment and other restricted sources | 122,681 | 102,799 |
| Total scholarships | 372,934 | 342,670 |
| Employee and dependent tuition benefits | 45,447 | 41,643 |
| Stipends | 87,718 | 91,212 |
| Work study | 1,762 | 1,545 |
| Total | $ 507,861 | $ 477,070 |

**Gifts**

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax-exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.56% to 3.49%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors.

*(All amounts in thousands of dollars)*

A summary of pledges receivable is as follows:

| | 2024 | 2023 |
|---|---|---|
| In one year or less | $ 167,622 | $ 176,583 |
| Between two and five years | 133,429 | 158,483 |
| Over five years | 128,394 | 103,681 |
| | 429,445 | 438,747 |
| Less: | | |
| Discount | (19,971) | (11,926) |
| Allowance for uncollectible amounts | (4,341) | (8,000) |
| Total | $ 405,133 | $ 418,821 |

**Grants and Contracts**

The university receives grant and contract revenue from governmental and private sources. The vast majority of such agreements are awarded to the university by government agencies and are considered conditional contributions. The principle condition attached to these awards is that the university must incur costs in accordance with the Office of Management and Budget's uniform guidance before costs can be reimbursed. The university generally recognizes revenue without donor restrictions as the related costs are incurred. These revenues include recoveries of indirect costs, also referred to as facilities and administrative costs, which is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of federally sponsored programs is at rates negotiated with the Department of Health and Human Services. In some cases, the sponsor will prepay amounts in anticipation of costs to be incurred. In those cases, amounts received in excess of costs incurred are recorded as deferred revenue.

The university's current population of federal grants and contracts have an average award range of 3 – 5 years. There is no assurance that government sponsored research awards will continue to be made at current levels as awards are subject to the availability of and annual appropriation of funds. The university estimates that the total amounts promised under these agreements for which conditions have not yet been fulfilled as of June 30, 2024 and 2023, approximate or exceed current annual grants and contracts activity.

**Patient Services Revenue**

Net patient services revenue is reported at the amount that reflects the consideration to which the university expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including health insurers and government programs), and others. Generally, the university bills the patient and third-party payers several days after the services are performed. Revenue is recognized as performance obligations are satisfied.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges which provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to

satisfy the obligation. Amounts receivable under physician service contracts with affiliated and unaffiliated hospitals are $149,341 and $72,943 at June 30, 2024 and 2023, respectively.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, the university has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

Generally, patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The university also provides services to uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. The university determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The university determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as there are a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. The effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Contractual adjustments to patient service revenue were $2,903,000 and $2,680,000 for the years ended June 30, 2024 and 2023, respectively.

The university has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. In certain instances, the university may enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The university reported patient receivables net of contractual adjustments of $201,430 and $151,641, at June 30, 2024 and 2023, respectively.

**Auxiliary Enterprises – Sales and Services**

Auxiliary enterprises sales and services revenue is primarily earned over-time utilizing the output method of measuring progress. Auxiliary enterprise sales and services contracts will generally constitute a single performance obligation as there is a single promise. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees with separate contracts for each type of service. Housing, dining services and parking fees are invoiced to undergraduate students at the beginning of each academic period. Payment is due upon invoice issuance. Graduate students and undergraduates who live off campus sign rental agreements providing for monthly rent payments. Generally, contracts for services in this category have a duration of one year or less. A contract liability is recorded for the delivery of performance obligations that is not completed prior to the fiscal year end.

*(All amounts in thousands of dollars)*

### Educational Activities – Sales and Services

Clinical trial revenue is earned over-time as the university provides services. The transaction price is negotiated with the customer and is usually based on standard rates for clinical services and the expected cost to complete the contract. Payment terms under these contracts vary but generally provide for the right to invoice the customer as work progresses, either based on units performed or the achievement of billing milestones. The university has determined that an input method using costs incurred as a basis to estimate revenue earned best depicts the pattern of transfer of control to the customer. In those limited cases where prepayments are significant, revenue is deferred until earned and a contract liability is recorded. Such amounts are reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Contracts in other educational sales and services cover a broad range of activities including laboratory services, executive education program fees and royalties. Revenue from the contracts in this category is earned over time as services are rendered. The measure of progress varies according to the nature of the services provided. Invoicing to customers is performed in the cadence required under the contracts and amounts invoiced generally are considered due upon receipt. Accruals for services provided but not yet invoiced are recorded at year end. Fees for executive education programs are often received in advance of the program and represent a contract liability. Such amounts are reported as deferred revenue and contract liabilities in the consolidated statement of financial position.

### Affiliated Hospital Revenues

Affiliated hospital revenue is earned over-time as the various services are provided as an integrated performance obligation as more fully described in footnote 13. The measure of progress towards completion of those obligations is based on the day-to-day operations of the university's School of Medicine and the affiliated hospitals. Payments are received under the agreement semiannually. Amounts receivable under the agreement are $93,955 and $88,097 at June 30, 2024 and 2023 respectively.

### Operating Results

The university's measure of operations as presented in the consolidated statements of activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the consolidated statements of activities as incurred for employee compensation, depreciation, interest, and supplies, services and other. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, contributions to be held in perpetuity, and other non-operating amounts.

### Income Taxes

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income, or consolidated for-profit affiliates incur taxes. The university is also subject to excise tax on net investment income and executive compensation. A provision for such taxes is included within accounts payable and accrued expenses on the consolidated statement of financial position and in investment returns net of endowment spending on the consolidated statement of activities.

*(All amounts in thousands of dollars)*

Management believes the university has no uncertain tax positions that require disclosure or adjustment to the consolidated financial statements.

**Related Parties**

The university has a number of related party entities, many of which are included in the consolidated financial statements as disclosed in footnote 1. The university is also party to affiliation agreements with hospitals for which significant related party transactions are described in footnote 6 and 13.

Members of the university's Board of Trustees, officers, and employees may periodically be directly or indirectly associated with organizations doing business with the university. Accordingly, the university has written conflict of interest policies that require disclosure of conflicts which may include financial interests in, or employment or board service with affiliated entities. Such relationships are subject to review and approval and may result in measures taken to manage any actual or perceived conflicts. Transactions between the university and members of its Board of Trustees, officers, employees, and their related entities, while not considered material to the consolidated financial statements, can include loans reported in accounts and notes receivables as well as contributions reported in gift revenue and pledges receivable.

The university invests in equity securities that are limited partnerships or equivalent entities which could be considered related parties.

**Recent Accounting Pronouncements**

ASU 2016-13, *Measurement of Credit Losses on Financial Instruments*, was issued by the FASB during June 2016 and was early adopted by the university during fiscal year 2021 with no significant impact to the university's consolidated financial statements. Subsequent updates, primarily codification improvements, have been made to Credit Losses (collectively, ASC 326) in recent years to expand upon or clarify proper accounting for the measurement of credit losses on financial instruments. The university has evaluated all subsequent updates and determined that no additional changes are needed to the consolidated financial statements or footnote disclosures.

During December 2023, the FASB issued ASU 2023-08, *Accounting for and Disclosure of Crypto Assets* which requires in-scope crypto assets to be measured at fair value with subsequent gains and losses recognized as change in net assets. This standard is effective for fiscal years beginning after December 15, 2024. Although not expected to be significant, university management is evaluating the impact this will have on the financial statements beginning in fiscal year 2026.

## 2. Fair Value

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

*(All amounts in thousands of dollars)*

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university's assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.

Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2024, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately $916,329.

*(All amounts in thousands of dollars)*

| | Quoted Prices in Active Markets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Measured at Net Asset Value | Balance June 30, 2024 |
|---|---|---|---|---|---|
| **Investments** | | | | | |
| Public equity | | | | | |
| Domestic | $ 38,875 | $ - | $ - | $ 1,055,572 | $ 1,094,447 |
| International | 235,729 | - | - | 1,713,925 | 1,949,654 |
| Fixed income - Nominal | - | 1,304,884 | - | - | 1,304,884 |
| Absolute return | - | - | 499 | 704,218 | 704,717 |
| Private capital | - | - | 250,416 | 7,456,226 | 7,706,642 |
| Short-term investments | 261,619 | 11,110 | - | - | 272,729 |
| Real assets | 57,223 | - | 78,746 | 1,031,790 | 1,167,759 |
| Other investments | 366,200 | 17,412 | 63,107 | 103 | 446,822 |
| Total investments at fair value | 959,646 | 1,333,406 | 392,768 | 11,961,834 | $ 14,647,654 |
| Investments not reported at fair value | | | | | |
| Affiliates - Equity basis | - | - | - | - | 41,971 |
| Accrued investment income | - | - | - | - | 8,314 |
| Total investments | $ 959,646 | $ 1,333,406 | $ 392,768 | $ 11,961,834 | $ 14,697,939 |

The following table presents the financial instruments carried at fair value as of June 30, 2023, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately $880,691.

| | Quoted Prices in Active Markets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Measured at Net Asset Value | Balance June 30, 2023 |
|---|---|---|---|---|---|
| **Investments** | | | | | |
| Public equity | | | | | |
| Domestic | $ 163,517 | $ - | $ 20,675 | $ 499,195 | $ 683,387 |
| International | 156,593 | - | - | 2,033,971 | 2,190,564 |
| Fixed income - Nominal | - | 1,298,983 | - | - | 1,298,983 |
| Absolute return | - | - | 476 | 672,715 | 673,191 |
| Private capital | - | - | 244,918 | 7,142,353 | 7,387,271 |
| Short-term investments | 378,660 | 5,226 | - | - | 383,886 |
| Real assets | 28,054 | - | 72,155 | 838,494 | 938,703 |
| Other investments | 621,067 | 23,093 | 63,759 | 165 | 708,084 |
| Total investments at fair value | 1,347,891 | 1,327,302 | 401,983 | 11,186,893 | $ 14,264,069 |
| Investments not reported at fair value | | | | | |
| Affiliates - Equity basis | - | - | - | - | 40,723 |
| Accrued investment income | - | - | - | - | 6,779 |
| Total investments | $ 1,347,891 | $ 1,327,302 | $ 401,983 | $ 11,186,893 | $ 14,311,571 |

*(All amounts in thousands of dollars)*

Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all. Trustees determine the valuation for beneficial interest trusts and split-interest agreements.

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private capital investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

*(All amounts in thousands of dollars)*

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2024:

| Investments | Fair Value June 30, 2024 | Unfunded Commitment (1) | Remaining Life (2) | Redemption Terms | Redemption Restrictions |
|---|---|---|---|---|---|
| Public equities | $ 3,044,101 | $ - | No Limit | Daily to annually, with same day-180 day notice | Lock-up provision periods range from none to 4 years. Certain investments include side pockets subject to external manager discretion. |
| Fixed income and short-term investments | 1,577,613 | - | No Limit | Daily, 1-2 days notice | No lock-up provision |
| Absolute return | 704,717 | - | No Limit | Quarterly to semi-annually with 45 – 180 days notice | Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion. |
| Private capital | 7,706,642 | 1,489,572 | 0 - 25 Years | Not eligible for redemption | Not redeemable |
| Real assets | 1,167,759 | 237,438 | 0 - 10 Years | Not eligible for redemption | Not redeemable |
| Total | $ 14,200,832 | $ 1,727,010 | | | |

Footnote (1): Includes $15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

*(All amounts in thousands of dollars)*

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2023:

| Investments | Fair Value June 30, 2023 | Unfunded Commitment (1) | Remaining Life (2) | Redemption Terms | Redemption Restrictions |
|---|---|---|---|---|---|
| Public equities | $ 2,873,951 | $ - | No Limit | Daily to annually, with same day-180 day notice | Lock-up provision periods range from none to 5 years. Certain investments include side pockets subject to external manager discretion. |
| Fixed income and short-term investments | 1,682,869 | - | No Limit | Daily, 1-2 days notice | No lock-up provision |
| Absolute return | 673,191 | - | No Limit | Quarterly to semi-annually with 45 – 180 days notice | Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion. |
| Private capital | 7,387,271 | 1,696,758 | 0 - 26 Years | Not eligible for redemption | Not redeemable |
| Real assets | 938,703 | 307,701 | 0 - 11 Years | Not eligible for redemption | Not redeemable |
| Total | $ 13,555,985 | $ 2,004,459 | | | |

Footnote (1): Includes $15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

### Public Equities

Public equities include investments in publicly–traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled commingled funds which are valued at NAV as described above. Investments held in custody accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

### Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

*(All amounts in thousands of dollars)*

### Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to equity hedged and event driven. These funds are valued at net asset value as described above.

### Private Capital

Investments in private capital strategies are made in targeted categories including growth equity, venture capital, distressed credit, and corporate finance. The majority of these assets are in non-redeemable drawdown fund structures and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

### Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in non-redeemable drawdown fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

### Level Three Investments

The following tables roll forward the consolidated statement of financial position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2024 and 2023.

| | Balance June 30, 2023 | Net Realized and Unrealized Gains (Losses) | Purchases, Sales and Settlements Net | Transfers in/(out) of Level 3, net | Balance June 30, 2024 |
|---|---|---|---|---|---|
| Investments (by strategy) | | | | | |
| Private capital | $ 244,918 | $ 11,097 | $ (5,599) | $ - | $ 250,416 |
| Real assets | 72,155 | 3,361 | 3,230 | - | 78,746 |
| Absolute return | 476 | 23 | - | - | 499 |
| Public equity | 20,675 | 1,467 | (22,142) | - | - |
| Other investments | 63,759 | 2,526 | (2,177) | (1,001) | 63,107 |
| Total | $ 401,983 | $ 18,474 | $ (26,688) | $ (1,001) | $ 392,768 |

| | Balance June 30, 2022 | Net Realized and Unrealized Gains (Losses) | Purchases, Sales and Settlements Net | Transfers in/(out) of Level 3, net | Balance June 30, 2023 |
|---|---|---|---|---|---|
| Investments (by strategy) | | | | | |
| Private capital | $ 328,880 | $ (97,330) | $ 8,368 | $ 5,000 | $ 244,918 |
| Real assets | 20,134 | (438) | 7,871 | 44,588 | 72,155 |
| Absolute return | - | (44) | - | 520 | 476 |
| Public equity | 21,759 | (1,084) | - | - | 20,675 |
| Other investments | 60,141 | 6,220 | (1,363) | (1,239) | 63,759 |
| Total | $ 430,914 | $ (92,676) | $ 14,876 | $ 48,869 | $ 401,983 |

*(All amounts in thousands of dollars)*

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2024 and 2023 respectively, reported as investment returns net of endowment spending in the consolidated statements of activities by type of investment is:

| | 2024 | 2023 |
|---|---|---|
| Private capital | $ 4,975 | $ (46,968) |
| Real assets | 3,004 | (1,196) |
| Absolute Return | (205) | (44) |
| Public equity | - | (1,083) |
| Other investments | 1,638 | 1,837 |
| Total | $ 9,412 | $ (47,454) |

## 3. Investment Return

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private capital categories, report investment returns net of fees.

| | 2024 | 2023 |
|---|---|---|
| Investment income | $ 95,018 | $ 72,234 |
| Pooled endowment dividends and interest income, net of investment management fees | (50,414) | (53,596) |
| Pooled endowment distribution in excess of income | 626,359 | 623,385 |
| Pooled endowment spending distribution | 575,945 | 569,789 |
| Investment gains (losses), net | 1,073,305 | (313,738) |
| Gains distributed as endowment distribution | (626,359) | (623,385) |
| Investment gains (losses) net of endowment spending distribution | 446,946 | (937,123) |
| Net investment return | $ 1,117,909 | $ (295,100) |

## 4. Endowment

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2024, the university's endowment consists of 4,410 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have

*(All amounts in thousands of dollars)*

been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as net assets with donor restrictions, (a) the original value of gifts donated to the donor-restricted endowment, (b) the original value of subsequent gifts to the donor-restricted endowment, (c) accumulations to the donor-restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of donor-restricted endowment funds that are not restricted in perpetuity are considered restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2024:

| | Without Donor Restriction | With Donor Restriction | Total |
|---|---|---|---|
| Donor-restricted endowment funds | $ - | $ 6,991,404 | $ 6,991,404 |
| Board-designated endowment funds | 4,439,294 | 575,328 | 5,014,622 |
| Total endowment funds | $ 4,439,294 | $ 7,566,732 | $ 12,006,026 |

Changes in endowment net assets for the year ended June 30, 2024:

| | Without Donor Restriction | With Donor Restriction | Total |
|---|---|---|---|
| **Endowment net assets, beginning of year** | $ 4,279,133 | $ 7,210,181 | $ 11,489,314 |
| Investment return | | | |
| Net investment income | (19,950) | (29,752) | (49,702) |
| Net increase in investments (realized and unrealized) | 416,632 | 643,817 | 1,060,449 |
| Total investment return | 396,682 | 614,065 | 1,010,747 |
| Gifts | 66 | 86,437 | 86,503 |
| Appropriation of endowment assets for expenditure | (227,918) | (348,027) | (575,945) |
| Net transfers of funds | 28,773 | 26,370 | 55,143 |
| Allocation of endowment return to treasurer's investment pool | (43,221) | (29,434) | (72,655) |
| Other activity | 5,779 | 7,140 | 12,919 |
| **Endowment net assets, end of year** | $ 4,439,294 | $ 7,566,732 | $ 12,006,026 |

*(All amounts in thousands of dollars)*

Of the amount classified as endowment net assets with donor restrictions, $4,520,483 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment net asset composition by type of fund as of June 30, 2023:

| | Without Donor Restriction | With Donor Restriction | Total |
|---|---|---|---|
| Donor-restricted endowment funds | $ - | $ 6,686,908 | $ 6,686,908 |
| Board-designated endowment funds | 4,279,133 | 523,273 | 4,802,406 |
| Total endowment funds | $ 4,279,133 | $ 7,210,181 | $ 11,489,314 |

Changes in endowment net assets for the year ended June 30, 2023:

| | Without Donor Restriction | With Donor Restriction | Total |
|---|---|---|---|
| **Endowment net assets, beginning of year** | $ 4,531,534 | $ 7,711,224 | $ 12,242,758 |
| Investment return | | | |
| Net investment income | (21,949) | (30,919) | (52,868) |
| Net decrease in investments (realized and unrealized) | (123,111) | (176,607) | (299,718) |
| Total investment return | (145,060) | (207,526) | (352,586) |
| Gifts | 73 | 92,228 | 92,301 |
| Appropriation of endowment assets for expenditure | (233,346) | (336,443) | (569,789) |
| Net transfers of funds | 34,426 | (35,363) | (937) |
| Allocation of endowment return to treasurer's investment pool | 87,624 | (28,762) | 58,862 |
| Other activity | 3,882 | 14,823 | 18,705 |
| **Endowment net assets, end of year** | $ 4,279,133 | $ 7,210,181 | $ 11,489,314 |

Of the amount classified as endowment net assets with donor restrictions, $4,352,086 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

*(All amounts in thousands of dollars)*

### Endowment by Purpose

The purpose of endowment funds as of June 30, 2024:

| | Without Donor Restriction | With Donor Restriction | Total |
|---|---|---|---|
| Restricted for general activities | $ 2,856,017 | $ 4,984,782 | $ 7,840,799 |
| Restricted for student assistance | 1,235,956 | 1,658,796 | 2,894,752 |
| Restricted for buildings and renovations | 347,321 | 889,223 | 1,236,544 |
| Life income | - | 33,931 | 33,931 |
| Total endowment net assets | $ 4,439,294 | $ 7,566,732 | $ 12,006,026 |

The purpose of endowment funds as of June 30, 2023:

| | Without Donor Restriction | With Donor Restriction | Total |
|---|---|---|---|
| Restricted for general activities | $ 2,752,888 | $ 4,746,584 | $ 7,499,472 |
| Restricted for student assistance | 1,190,110 | 1,572,685 | 2,762,795 |
| Restricted for buildings and renovations | 336,135 | 855,565 | 1,191,700 |
| Life income | - | 35,347 | 35,347 |
| Total endowment net assets | $ 4,279,133 | $ 7,210,181 | $ 11,489,314 |

### Endowment Funds with Deficits

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they remain classified as net assets with donor restrictions. Deficits of this nature were immaterial as of June 30, 2024 and 2023. The deficits resulted largely from unfavorable market fluctuations.

### Return Objectives and Risk Parameters

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

### Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

*(All amounts in thousands of dollars)*

**Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives**

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2024, the spending rate from the pooled endowment was 4.9% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

The university's endowment assets at June 30 are as follows:

| | 2024 | 2023 |
|---|---|---|
| Pooled endowment and other funds | $ 12,951,263 | $ 12,390,790 |
| Life income trusts and pools | 66,512 | 69,602 |
| Externally administered trusts | 35,478 | 33,474 |
| Separately invested endowment | 8,236 | 9,037 |
| Total | 13,061,489 | 12,502,903 |
| Less: Operating funds invested in pool | (1,015,074) | (991,129) |
| Net endowment assets | $ 12,046,415 | $ 11,511,774 |

The amounts above include term endowments of $139,503 and $132,188 as of June 30, 2024 and 2023, respectively.

## 5. Liquidity and Availability of Resources

At June 30, 2024 and 2023, the university's financial assets available for general expenditures within one year of the balance sheet date are as follows:

| | 2024 | 2023 |
|---|---|---|
| Total assets at year end | $ 20,486,807 | $ 19,792,327 |
| Less: | | |
| Accounts and notes receivable due in more than one year | (96,107) | (92,742) |
| Pledges receivable unavailable for general expenditure | (273,473) | (294,173) |
| Donor-restricted endowment funds | (7,248,777) | (6,831,617) |
| Board-designated endowment funds | (4,797,638) | (4,680,157) |
| Other long-term investments | (1,647,649) | (1,783,702) |
| Right-of-use assets | (88,882) | (93,447) |
| Other assets | (433,132) | (362,291) |
| Fixed assets | (3,794,317) | (3,566,162) |
| Total financial assets available within one year | $ 2,106,832 | $ 2,088,036 |

*(All amounts in thousands of dollars)*

The university's endowment funds consist of donor-restricted and board-designated endowment funds. As described in Note 4, the university has an endowment spending distribution policy with a spending rate range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For fiscal year 2024, the Board of Trustees approved a spending rate which will generate an endowment payout equaling or exceeding that of fiscal year 2023, including an allocation to the treasurer's investment pool, which will be available for operations during fiscal year 2024.

In addition to these available financial assets, the university's annual expenditures will be primarily funded by current year operating revenues including tuition, patient services income, and sponsored research income. As part of the university's liquidity management, a policy is in place to structure its financial assets to be available as general expenditures, liabilities, and other obligations come due. The university also invests cash in excess of daily requirements in short-term investments. Furthermore, although the university does not intend to spend from its board-designated endowment funds other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment that are free from investment restrictions could be made available if necessary. Other long-term investments are primarily composed of amounts designated by the university as reserves. Such investments are without donor restriction and could be drawn upon in the event of extreme stress. In the event of an unanticipated liquidity need, the university could also draw upon $430,000 of available lines of credit at June 30, 2024.

## 6. Accounts and Notes Receivable

Accounts and notes receivable at June 30 were as follows:

| | 2024 | 2023 |
|---|---|---|
| Patient services | $ 594,512 | $ 526,077 |
| Student and parent loans | 68,282 | 70,468 |
| Due from affiliate hospitals | 252,320 | 190,783 |
| Sponsored project receivables | 167,208 | 158,210 |
| Other | 153,674 | 159,244 |
| | 1,235,996 | 1,104,782 |
| Less: Allowance for contractual adjustments and doubtful accounts | (399,066) | (381,567) |
| Total | $ 836,930 | $ 723,215 |

*(All amounts in thousands of dollars)*

## 7. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2024 and 2023 consists of the following:

| | Rates at June 30, 2024 | Maturity | 2024 | 2023 |
|---|---|---|---|---|
| **Missouri Health and Educational Facilities Authority** | | | | |
| $88,000 of 2000B and C Series Variable Rate Bonds, due in full | 3.60% - 4.90% | March 1, 2040 | $ 88,000 | $ 88,000 |
| $25,135 of 2003B Series Variable Rate Bonds, due in full | 4.00% - 4.90% | February 15, 2033 | 25,135 | 25,135 |
| $77,495 of 2011C Series Revenue Bonds, due serially from November 15, 2012 to November 15, 2037 | 0.75% - 5.06% | November 15, 2037 | 42,165 | 44,740 |
| $200,785 of 2012A Series Revenue Bonds, due serially from February 15, 2023 to February 15, 2047 | 2.39% - 3.69% | February 15, 2047 | 180,785 | 180,785 |
| $150,000 of 2014A Series Revenue Bonds, due in full | 4.07% | October 15, 2044 | 150,000 | 150,000 |
| $402,920 of 2016A Series Revenue Bonds, due in full January 15, 2036 ($109 ,300) and January 15, 2046 ($293,620) | 3.47% - 3.65% | January 15, 2036 and 2046 | 402,920 | 402,920 |
| $272,750 of 2016 B Series Revenue Bonds, due in full | 3.09% | September 15, 2051 | 272,750 | 272,750 |
| $375,000 of 2017 A Series Revenue Bonds, due in full | 3.65% | August 15, 2057 | 375,000 | 375,000 |
| $450,000 of 2020 A Series Revenue Bonds, due in full | 3.23% | May 15, 2050 | 450,000 | 450,000 |
| **Other Bonds:** | | | | |
| $131,435 of 2015A Series Taxable Bonds, due in full | 3.79% | October 15, 2055 | 131,435 | 131,435 |
| $1,000,000 of 2022 Series Taxable Bonds, due in full on April 15, 2054 ($500,000) and April 15, 2122 ($500,000) | 3.52% - 4.35% | April 15, 2054 and 2122 | 1,000,000 | 1,000,000 |
| Other notes payable with various maturities | | | 162,407 | 153,484 |
| Total outstanding notes and bonds payable | | | 3,280,597 | 3,274,249 |
| Unamortized original issue premiums/discounts and cost of issuance, net | | | (14,289) | (14,774) |
| Total | | | $3,266,308 | $3,259,475 |

Bonds payable are redeemable at the option of the university at various times from 2024 through 2122. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintains a ratio of expendable financial resources to bonds and notes payable of at least 1.25 times. The university is in compliance with this covenant. During 2024 and 2023, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled $116,299 and $116,923, respectively.

*(All amounts in thousands of dollars)*

Maturities on notes and bonds payable for the next five fiscal years are as follows:

| | |
|---|---|
| 2025 | 25,892 |
| 2026 | 134,837 |
| 2027 | 32,522 |
| 2028 | 2,607 |
| 2029 | 2,722 |
| Thereafter | 3,082,017 |

The university has other lines of credit, which generally expire annually, aggregating to $430,000, of which $430,000 is available at June 30, 2024. The university expects that these lines of credit will be renewed but can make no assurances.

## 8. Operating Leases

The university and its consolidated affiliates primarily lease laboratories, office space, and medical offices for educational, research, and patient care purposes under operating leases expiring through fiscal 2034. At June 30, 2024 and 2023, the weighted average remaining lease term was 4.9 and 5.8 years and the weighted average discount rate was 4.01% and 3.65%, respectively. Lease expense is included in supplies, services, and other on the consolidated statement of activities.

The undiscounted cash flows due by fiscal year related to significant non-cancelable operating leases with initial terms in excess of one year as of June 30, 2024, along with a reconciliation to the discounted amount recorded as of June 30, 2024 were as follows:

| | | |
|---|---|---|
| 2025 | | 27,089 |
| 2026 | | 26,247 |
| 2027 | | 20,714 |
| 2028 | | 15,953 |
| 2029 | | 9,537 |
| Thereafter | | 13,382 |
| Total minimum lease payments | $ | 112,922 |
| Less: Imputed interest | | (14,207) |
| Total lease liabilities | $ | 98,715 |

## 9. Derivative and Other Financial Instruments

The university utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the university uses a third-party manager to execute, settle and manage the positions on a non-discretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and quarterly as well as at June 30, with the resulting changes in the values of the contracts either

added to or deducted from the university's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the consolidated statements of activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the university invests pose no off-balance sheet risk to the university due to the limited liability structure of the investments. Derivatives are also used to manage operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

## 10. Functional Expenses

Operating expenses are reported on the consolidated statements of activities in natural categories. Expenses reported by functional categories include allocations of costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs.

Operating expenses by functional and natural classification for the year ended June 30, 2024 are as follows:

| | Compensation and benefits | Supplies, services and other | Depreciation | Interest | Total |
|---|---|---|---|---|---|
| Instruction | $ 1,831,889 | $ 1,090,341 | $ 81,708 | $ 22,267 | $ 3,026,205 |
| Research | 484,891 | 288,640 | 79,214 | 39,933 | 892,678 |
| Academic Support | 399,032 | 50,998 | 25,817 | 13,970 | 489,817 |
| Student Services | 69,864 | 79,765 | 8,091 | 3,584 | 161,304 |
| Institutional Support | 244,746 | 38,943 | 12,238 | 489 | 296,416 |
| Auxiliary Enterprises | 23,014 | 70,153 | 47,885 | 24,051 | 165,103 |
| Other | 25,679 | 24,896 | 568 | 493 | 51,636 |
| Total | $ 3,079,115 | $ 1,643,736 | $ 255,521 | $ 104,787 | $ 5,083,159 |

Operating expenses by functional and natural classification for the year ended June 30, 2023 are as follows:

| | Compensation and benefits | Supplies, services and other | Depreciation | Interest | Total |
|---|---|---|---|---|---|
| Instruction | $ 1,668,440 | $ 972,454 | $ 69,197 | $ 33,256 | $ 2,743,347 |
| Research | 435,867 | 279,356 | 67,630 | 17,873 | 800,726 |
| Academic Support | 367,454 | 54,389 | 23,522 | 12,275 | 457,640 |
| Student Services | 65,834 | 66,591 | 6,179 | 2,910 | 141,514 |
| Institutional Support | 186,142 | 38,710 | 16,630 | 2,078 | 243,560 |
| Auxiliary Enterprises | 20,971 | 58,700 | 41,612 | 25,154 | 146,437 |
| Other | 25,603 | 11,309 | 199 | 192 | 37,303 |
| Total | $ 2,770,311 | $ 1,481,509 | $ 224,969 | $ 93,738 | $ 4,570,527 |

*(All amounts in thousands of dollars)*

## 11. Commitments and Contingencies

At June 30, 2024 and 2023, the university had outstanding commitments under certain construction contracts in the amount of $122,207 and $248,572, respectively.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the consolidated statements of financial position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2024 and 2023, respectively, were $113,686 and $104,012. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, consolidated statements of activities, financial position or liquidity of the university.

## 12. Retirement Plan

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. The amount of contribution made by the university is based on employee's hire date and/or age. While participant contributions are fully vested when contributions are made, university contributions are subject to vesting provisions based on employee's hire date. The university's share of the cost of these benefits in 2024 and 2023 was $153,327 and $121,010, respectively.

## 13. Agreements with Affiliated Hospitals

The university has an affiliation agreement with BJC in relation to Barnes Jewish Hospital (BJH), St. Louis Children's Hospital (SLCH), and Barnes Jewish West County Hospital (BJWCH), collectively the Hospitals, which expires December 31, 2027, but may be canceled upon a one-year written notice by either party. This agreement relates to various operating

activities of the Hospitals including Orthopedic Center (OC) in Chesterfield, Siteman Cancer Center – South County, Center for Advanced Medicine (CAM) in South County, BJH Psychiatric Support Center (PSC), Children's Specialty Care Center in Town and Country, and Children's Specialty Care Center in South County.

Under the terms of the affiliation agreement, the university trains and supervises medical residents and interns and manages certain clinical and research activities of the Hospitals. The Hospitals compensate the university for services provided through a fixed annual base payment (adjusted annually for inflation) plus an additional variable payment based on the combined net operating income of the Hospitals. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. Payments to the university under affiliation agreements are reported as affiliated hospital revenue on the consolidated statements of activities (see footnote 1). During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of $35,590 and $40,855 were received or accrued as gifts on the consolidated statements of activities under the agreement during 2024 and 2023, respectively.

## 14. Subsequent Events

The university has performed an evaluation of subsequent events through September 27, 2024, which is the date the consolidated financial statements were issued. In July 2024, the university signed a revised and extended 45-year affiliation agreement with BJC Health System; expanding the communities served and enhancing the services provided under the existing agreement (see footnote 13). As part of the agreement, effective July 1, 2024, the university transitioned its oncology chemotherapy infusion services and retail pharmacy services to hospital outpatient services of the BJC Health System. Within the consolidated statement of activities as of June 30, 2024, for the service lines that have been subsequently transferred, the university recognized patient services revenue of approximately $625,000 and operating expenses of approximately $550,000. The university will continue to receive compensation for services provided and clinical operating performance, including the transitioned service lines, based on revised calculations which will be reflected in the financial statements for the period ending June 30, 2025.

# Supplemental Information

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| **Research and Development Cluster** | | | | | |
| **DEPARTMENT OF DEFENSE** | | | | | |
| **Advanced Research Projects Agency** | | | | | |
| Research and Technology Development | 12.910 | | | $ 1,543,477 | $ 205,964 |
| Research and Technology Development | 12.910 | Columbia University | HR0011-22-2-0022 | 116,489 | - |
| Research and Technology Development | 12.910 | Vanderbilt University Medical Center | HR00111820001 | 73,224 | - |
| **Defense Advanced Research Projects Agency** | | | | | |
| Defense Advanced Research Projects Agency | 12.RD | Charles River Analytics Inc | N6600121C4013 | 673,310 | - |
| Defense Advanced Research Projects Agency | 12.RD | Tai-Yang Research Company | N66001-24-C-4016 | 56,449 | - |
| **Defense Intelligence Agency** | | | | | |
| Centers for Academic Excellence | 12.598 | Georgia Institute Of Technology | W911W6-21-2-001 | 83,066 | - |
| **Defense Threat Reduction Agency** | | | | | |
| Defense Threat Reduction Agency | 12.RD | Massachusetts General Hospital | HDTRA122C0006 | 283,407 | - |
| Defense Threat Reduction Agency | 12.RD | Najit Technologies, Inc. | W15QKN1691002 | 204,061 | - |
| Defense Threat Reduction Agency | 12.RD | University Of Pittsburgh | W15QKN1691002 | 1,347,213 | - |
| **Department of Defense** | | | | | |
| Department of Defense | 12.RD | Barron Associates | W81XWH22C0068 | 63,311 | - |
| Department of Defense | 12.RD | BlueHalo | HM0476-21-C-0004 | 95,803 | - |
| Department of Defense | 12.RD | BlueHalo | HQ0860-21-C-7137 | 89,613 | - |
| Department of Defense | 12.RD | Cornerstone Research Group Inc | W81XWH-22-11062 | 118,439 | - |
| Department of Defense | 12.RD | Cure HHT Foundation | W81XWH2110827 | 430 | - |
| Department of Defense | 12.RD | Eccalon LLC | 47QTCA18D00DK | 18,054 | - |
| Department of Defense | 12.RD | HII Mission Technologies Corp. | FA807518D0002 | 5,681 | - |
| Department of Defense | 12.RD | Johns Hopkins University | X81XWH1620060 | (825) | - |
| Department of Defense | 12.RD | Mainstream Engineering Corporation | HQ086023C7520 | 599 | - |
| Department of Defense | 12.RD | NervGen Pharma Corp | W81XWH1590001 | 348,897 | - |
| Department of Defense | 12.RD | University Of Alabama Birmingham | W81XWH2230001 | 5,720 | - |
| Department of Defense | 12.RD | University Of Pittsburgh | W81XWH209C003 | 383,456 | - |
| **Department of the Air Force, Material Command** | | | | | |
| Air Force Defense Research Sciences Program | 12.800 | | | 588,169 | - |
| Air Force Defense Research Sciences Program | 12.800 | Pennsylvania State University | FA95502110202 | 82,506 | - |
| Air Force Defense Research Sciences Program | 12.800 | Princeton University | FA9550202024 1 | 211,885 | - |
| Air Force Defense Research Sciences Program | 12.800 | University of Colorado | FA9550-20-1-0076 | 71,271 | - |
| Air Force Defense Research Sciences Program | 12.800 | University of Washington | FA9550-20-1-0074 | 96,989 | - |
| Air Force Defense Research Sciences Program | 12.800 | West Virginia University | FA9550-21-1-0088 | 169,007 | - |
| Air Force Defense Research Sciences Program | 12.800 | Worcester Polytechnic Institute | FA95502210054 | 57,075 | - |
| **Department of the Navy, Office of the Chief of Naval Research** | | | | | |
| Basic and Applied Scientific Research | 12.300 | | | 1,691,827 | 531,617 |
| Basic and Applied Scientific Research | 12.300 | Indiana University–Purdue University Indianapolis | N000142112630 | 251,365 | - |
| Basic and Applied Scientific Research | 12.300 | University Of California Davis | N000141712961 | 202,595 | - |
| Basic and Applied Scientific Research | 12.300 | University Of Southern California | N000141812632 | 19,256 | - |
| **National Security Agency** | | | | | |
| National Security Agency | 12.RD | North Carolina State University | H98230-l 9-D-00 12/0004 | 28,767 | - |
| National Security Agency | 12.RD | North Carolina State University | H98230-l 9-D-00 12/0004LAS | 128,806 | - |
| Basic, Applied, and Advanced Research in Science and Engineering | 12.630 | Battelle Memorial Institute | W911SR-15-2-0001 | 18,144 | - |
| Basic, Applied, and Advanced Research in Science and Engineering | 12.630 | University Of Iowa | FA95502010346 | 91,477 | - |
| Basic, Applied, and Advanced Research in Science and Engineering | 12.630 | University of Pennsylvania | W911NF-17-2-0181 | 8,813 | - |
| **U.S. Army Material Command** | | | | | |
| Basic Scientific Research | 12.431 | | | 702,040 | 227,016 |
| Basic Scientific Research | 12.431 | Missouri University of Science and Technology | W911NF2120262 | 131,639 | - |
| Basic Scientific Research | 12.431 | University Of Kentucky | FA95502110227 | 18,644 | - |
| Basic Scientific Research | 12.431 | University of Michigan | W911NF1810208 | 136,238 | - |
| Basic Scientific Research | 12.431 | University of Minnesota | W911NF1810240 | 104,598 | - |
| Basic Scientific Research | 12.431 | University of Southern California | W911NF2110327 | 28,407 | - |
| **U.S. Army Medical Command** | | | | | |
| Military Medical Research and Development | 12.RD | | | 814,298 | 365,008 |
| Military Medical Research and Development | 12.420 | | | 12,508,540 | 1,564,147 |
| Military Medical Research and Development | 12.420 | Cedars Sinai Medical Center | HT94252310269 | 110,768 | - |
| Military Medical Research and Development | 12.420 | Fred Hutchinson Cancer Center | W81XWH-22-2-0003 | 329,030 | - |
| Military Medical Research and Development | 12.420 | IDBiologics Inc | W81XWH1910405 | 385 | - |
| Military Medical Research and Development | 12.420 | Johns Hopkins University | W81XWH10580 | 43,456 | - |
| Military Medical Research and Development | 12.420 | Saint Louis University | W81XWH2010241 | (497) | - |
| Military Medical Research and Development | 12.420 | University Of Alabama Birmingham | W81XWH1720037 | 2,975 | - |
| Military Medical Research and Development | 12.420 | University Of Alabama Birmingham | W81XWH2210924 | 390,895 | - |
| Military Medical Research and Development | 12.420 | University of Illinois at Urbana-Champaign | W81XWH2110062 | 9,906 | - |
| Military Medical Research and Development | 12.420 | University Of Iowa | W81XWH2210683 | 123,945 | - |
| Military Medical Research and Development | 12.420 | University of Missouri System | W81XWH2110173 | 16,429 | - |
| Military Medical Research and Development | 12.420 | University Of North Carolina Chapel Hill | W81XWH1910117 | (3,066) | - |
| Military Medical Research and Development | 12.420 | University of Pittsburgh | W81XWH1720073 | 2,185 | - |
| Military Medical Research and Development | 12.420 | University Of South Carolina | W81XWH1920051 | 32,770 | - |
| Military Medical Research and Development | 12.420 | University Of Texas MD Anderson Cancer Center | HT94252310239 | 81,665 | |
| Military Medical Research and Development | 12.420 | Veterans Research & Education Foundation of St. Louis | W81XWH2010785 | 7,715 | - |
| Military Medical Research and Development | 12.420 | Veterans Research & Education Foundation of St. Louis | W81XWH2210602 | 65,051 | - |
| Military Medical Research and Development | 12.420 | Weill Medical College of Cornell University | W81XWH1810667 | (15,624) | - |
| TOTAL DEPARTMENT OF DEFENSE | | | | 24,870,218 | 2,893,752 |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| **DEPARTMENT OF EDUCATION** | | | | | |
| **Office of Postsecondary Education** | | | | | |
| Overseas Programs - Doctoral Dissertation Research Abroad | 84.022 | | | 36,691 | - |
| **Office of Special Education and Rehabilitative Services** | | | | | |
| **Education Research, Development and Dissemination** | 84.305 | Indiana University | R305N210035 | 32,412 | - |
| Special Education - Personnel Development to Improve Services and Results for Children with Disabilities | 84.325 | | | 667,620 | - |
| TOTAL DEPARTMENT OF EDUCATION | | | | 736,723 | - |
| **DEPARTMENT OF ENERGY** | | | | | |
| **Department of Energy** | | | | | |
| Office of Science Financial Assistance Program | 81.049 | | | 5,549,284 | 667,791 |
| Office of Science Financial Assistance Program | 81.049 | Aerosol Dynamics Inc | DESC0023627 | 117,700 | - |
| Office of Science Financial Assistance Program | 81.049 | Dartmouth College | DE-SC0022267 | 50,633 | - |
| Office of Science Financial Assistance Program | 81.049 | Georgia Institute Of Technology | DE-SC0012577 | (598) | - |
| Office of Science Financial Assistance Program | 81.049 | Iowa State University Of Science And Technology | DE-SC0023495 | 109,663 | - |
| Office of Science Financial Assistance Program | 81.049 | Michigan State University | DE-SC0013617 | 154,473 | - |
| Office of Science Financial Assistance Program | 81.049 | TDA Research Inc | DESC0018502 | 52,753 | - |
| Office of Science Financial Assistance Program | 81.049 | University Of Delaware | DE-SC0023085/UDR0000327 | 112,917 | - |
| Office of Science Financial Assistance Program | 81.049 | University of Texas at Dallas | DE-SC0022069 | 63,276 | - |
| Office of Science Financial Assistance Program | 81.049 | University Of Wisconsin | DE-SC0021985 | 92,063 | - |
| Renewable Energy Research and Development | 81.087 | | | 1,356,350 | 344,706 |
| Renewable Energy Research and Development | 81.087 | University at Buffalo | DE-EE0010750 | 17,211 | - |
| Fossil Energy Research and Development | 81.089 | | | 1,514,548 | 444,433 |
| Fossil Energy Research and Development | 81.089 | GTI Energy | DE-FE0031909 | 118,052 | |
| Fossil Energy Research and Development | 81.089 | Texas A&M University | DE-EE0032108 | 110,725 | - |
| Stewardship Science Grant Program | 81.112 | | | 101,825 | - |
| Stewardship Science Grant Program | 81.112 | Krell Institute | DENA0003960 | 41,333 | - |
| Stewardship Science Grant Program | 81.112 | Texas A&M University | DENA0003841 | 45,312 | |
| Stewardship Science Grant Program | 81.112 | Texas A&M University | DE-NA0004150 | 18,310 | - |
| Advanced Research Projects Agency - Energy | 81.135 | | | 766,776 | 441,226 |
| Department of Energy | 81.RD | Fermi National Accelerator Lab | DEAC0207CH11359 | 300,925 | - |
| Department of Energy | 81.RD | Honeywell International Inc. | N000522331 | 18,363 | - |
| Department of Energy | 81.RD | Honeywell International Inc. | N000523128 | 43,607 | - |
| Department of Energy | 81.RD | Lawrence Berkeley National Laboratory | DEAC0205CH11231 | (4,540) | - |
| Department of Energy | 81.RD | National Renewable Energy Laboratory | DE-AC36-08GO28308 | 100,691 | - |
| Department of Energy | 81.RD | Pacific Northwest National Laboratory | DE-AC05-76RL01830 | 351,987 | - |
| TOTAL DEPARTMENT OF ENERGY | | | | 11,203,639 | 1,898,156 |
| **DEPARTMENT OF HEALTH AND HUMAN SERVICES** | | | | | |
| **Administration for Children and Families** | | | | | |
| Child Abuse and Neglect Discretionary Activities | 93.670 | | | 50,598 | 33,741 |
| Child Abuse and Neglect Discretionary Activities | 93.670 | Vision for Children at Risk Inc | PACTSTL | 111,356 | - |
| **Administration for Community Living** | | | | | |
| ACL National Institute on Disability, Independent Living, and Rehabilitation Research | 93.433 | | | 198,201 | 7,269 |
| ACL National Institute on Disability, Independent Living, and Rehabilitation Research | 93.433 | University of Wisconsin, Milwaukee | 90IFDV0006 | (941) | - |
| ACL Assistive Technology State Grants for Protection and Advocacy | 93.843 | Tulane University | 5R01HL12242608 | 71,048 | - |
| **Advanced Research Projects Agency for Health (ARPA-H)** | | | | | |
| Advanced Research Projects Agency for Health (ARPA-H) | 93.384 | | | 1,342,150 | 22,225 |
| **Agency for Healthcare Research and Quality** | | | | | |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | | | 2,648,243 | 494,397 |
| COVID-Research on Healthcare Costs, Quality and Outcomes | 93.226 | | | 462,728 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | Children's Hospital Of Philadelphia (The) | 5R01HS02742803 | 56,914 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | Denver Health and Hospital Authority | 1R01HS029153-01 | 29,046 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | Denver Health and Hospital Authority | 5R01HS02915302 | 47,727 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | Ohio University | 1R03HS02940701A1 | 8,975 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | Thomas Jefferson University | 1R18HS029791-01 | 29,474 | - |
| COVID-Research on Healthcare Costs, Quality and Outcomes | 93.226 | Trustees Of Columbia University In the City Of New York | 1R01HS02845401A1 | 205,151 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | Tufts College | 1R01HS028650-01A1 | 12,810 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | University Of Chicago | 5R01HS02780402 | 52,366 | - |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | University of Michigan | 1R18HS028787-01A1 | 23,095 | - |
| **Centers for Disease Control** | | | | | |
| Chronic Diseases: Research, Control, and Prevention | 93.068 | Armor Medical Inc | 1R43DP006818-01-00 | 37,122 | - |
| Birth Defects and Developmental Disabilities, Prevention, and Surveillance | 93.073 | | | 286,692 | 52,815 |
| Birth Defects and Developmental Disabilities, Prevention, and Surveillance | 93.073 | Johns Hopkins University | 5U01DD00129702 | 23,352 | - |
| Blood Disorder Program: Prevention, Surveillance, and Research | 93.080 | | | 56,330 | - |
| Blood Disorder Program: Prevention, Surveillance, and Research | 93.080 | University of Texas Health Science Center at Houston | NU27DD000020-01-00 | 15,105 | - |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | | | 1,747,786 | 209,550 |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | Emory University | 6U54CK000601-02-01 | 53,828 | - |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | North Carolina State University | 5U01CK00058703 | 41,353 | - |
| COVID-Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | North Carolina State University | 5U01CK00058703 | 2,458 | |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | Rush University Medical Center Obligated Group | U54CK000607 | 14,463 | - |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | Trustees Of The University Of Pennsylvania | 6U54CK000610-03-01 | 18,008 | - |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | University Of Iowa | 6 U54CK000613-01-01 | 10,578 | - |
| Prevention of Disease, Disability, and Death by Infectious Diseases | 93.084 | University Of Iowa | 6U54CK00061301 | 196,568 | - |
| Centers for Research and Demonstration for Health Promotion and Disease Prevention | 93.135 | | | 1,017,982 | - |
| Injury Prevention and Control Research and State and Community Based programs | 93.136 | | | 314,295 | 117,328 |
| Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects | 93.185 | | | 2,276,119 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| COVID-Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects | 93.185 | | | 47,298 | |
| State Rural Hospital Flexibility Program | 93.241 | The National Association Of Chronic Disease Directors | 5NU38OT000286-05-02 | 188,965 | - |
| Occupational Safety and Health Program | 93.262 | | | 16,378 | - |
| Occupational Safety and Health Program | 93.262 | Center for Construction Research and Training | U60OH009762 | 280,095 | - |
| Occupational Safety and Health Program | 93.262 | Center for Construction Research and Training | U60-OH009762-11 | 46,647 | - |
| Occupational Safety and Health Program | 93.262 | The Regents of the University of California | 5R01OH01166104 | 140,033 | - |
| Occupational Safety and Health Program | 93.262 | University Of Iowa | 5U19OH00886817 | 39,785 | - |
| Occupational Safety and Health Program | 93.262 | University Of Iowa | 5U19OH00886818 | 81,167 | - |
| Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) | 93.323 | University of Washington | NU50CK000515 | 12,527 | - |
| Childhood Obesity Research Demonstration | 93.349 | | | 259,895 | 171,245 |
| Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health | 93.421 | Children's Hospital Corporation | 6NU38OT00028805 | 156,588 | - |
| Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health | 93.421 | The National Association Of Chronic Disease Directors | 5NU38OT0002863 | (14,239) | 1,204 |
| Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health | 93.421 | The National Association Of Chronic Disease Directors | 5NU38OT0002864 | 334 | - |
| Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health | 93.421 | The National Association Of Chronic Disease Directors | 5NU38OT0002865 | (9,781) | 385 |
| National Organizations for Chronic Disease Prevention and Health Promotion | 93.809 | National Association For Chronic Disease Director | 5NU58DP00651003 | 30,378 | 5,626 |
| National Organizations for Chronic Disease Prevention and Health Promotion | 93.809 | National Association For Chronic Disease Director | 5NU58DP00651004 | 21,804 | - |
| National Organizations for Chronic Disease Prevention and Health Promotion | 93.809 | National Association For Chronic Disease Director | 5NU58DP00651005 | 51,217 | 16,687 |
| Capacity Building Assistance for High-Impact HIV Prevention | 93.834 | | | 1,009,964 | 129,606 |
| Sexually Transmitted Diseases (STD) Provider Education Grants | 93.978 | | | 968,647 | 37,158 |
| Centers for Disease Control | 93.RD | | | 2,069,432 | 369,142 |
| Centers for Disease Control | 93.RD | St. Louis County | HE2022-0108 | 137,122 | - |
| Centers for Disease Control | 93.RD | St. Louis County | HE2023-0012 | 93,945 | 51,009 |
| Centers for Disease Control | 93.RD | Vanderbilt University Medical Center | 75D30122C14944 | 94,681 | - |
| Centers for Disease Control | 93.RD | Wayne State University | 75D30121C11813 | 111,819 | - |
| **Food and Drug Administration** | | | | | - |
| Food and Drug Administration_Research | 93.103 | Cumberland Pharmaceuticals | 1R01FD00637101A1 | 19,156 | - |
| Food and Drug Administration_Research | 93.103 | New York Medical College | 5R01FD00636304 | 16,549 | - |
| Food and Drug Administration_Research | 93.103 | Trustees Of Columbia University In the City Of New York | 5R01FD00574504 | 23,836 | - |
| **Health Resources and Services Administration** | | | | | - |
| Maternal and Child Health Federal Consolidated Programs | 93.110 | Boston University | 6 U1TMC31757-05-01 | 54,214 | - |
| Maternal and Child Health Federal Consolidated Programs | 93.110 | Cure HHT Foundation | 1UP4MC464040100 | 112,114 | - |
| Maternal and Child Health Federal Consolidated Programs | 93.110 | University of Missouri System | AOC19380201/U4J47106 | 17,573 | - |
| Maternal and Child Health Federal Consolidated Programs | 93.110 | University of Texas Health Science Center at Houston | 5H30MC24051-12-00 | 21,848 | - |
| Coordinated Services and Access to Research for Women, Infants, Children, and Youth | 93.153 | | | 1,052,029 | 89,081 |
| Rural Health Research Centers | 93.155 | University of Iowa | 2U1CRH20419-12-00 | 112,704 | - |
| Rural Health Research Centers | 93.155 | University of Iowa | 5U1GRH07633-14-00 | (606) | - |
| Mental and Behavioral Health Education and Training Grants | 93.732 | | | 820,841 | - |
| **IMMED Office of the Secretary of Health and Human Services** | | | | | - |
| Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development | 93.863 | | | 465,418 | - |
| Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development | 93.RD | Technical Resources International Inc | HHSO100201400002I | 17,293 | - |
| Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development | 93.RD | University of Pittsburgh | 75A50123C00047 | 21,719 | - |
| **National Institutes of Health** | | | | | |
| Environmental Health | 93.113 | | | 1,280,160 | 119,208 |
| Environmental Health | 93.113 | Dignity Health dba St. Joseph's Hospital & Medical Center | 7R01ES026891-06 | 8,602 | - |
| Environmental Health | 93.113 | Dignity Health dba St. Joseph's Hospital & Medical Center | 7R01ES02148808 | 378,275 | - |
| Environmental Health | 93.113 | New York University | 1R01ES03546801 | 50,278 | - |
| Environmental Health | 93.113 | Northwestern University | 5R01ES03180903 | 10,105 | - |
| Environmental Health | 93.113 | Trustees Of Columbia University In the City Of New York | 5R01ES03061605 | 93,229 | - |
| Environmental Health | 93.113 | University Of Louisville | 5R01ES02984603 | 25,319 | - |
| Environmental Health | 93.113 | University Of Maryland | 5R01ES03430302 | 100,670 | - |
| Environmental Health | 93.113 | University Of Southern California | 5R01ES03396102 | 130,329 | - |
| Oral Diseases and Disorders Research | 93.121 | | | 1,444,370 | 38,900 |
| Oral Diseases and Disorders Research | 93.121 | Case Western Reserve University | 2R01DE026923-06A1 | 10,214 | - |
| Oral Diseases and Disorders Research | 93.121 | Research Institute at Nationwide Children's Hospital | 7R01DE02829604 | 18,201 | - |
| Oral Diseases and Disorders Research | 93.121 | TetraImaging, LLC | 1R1DE02972701A1 | 3,200 | - |
| Oral Diseases and Disorders Research | 93.121 | Stanford University | 1R01DE030894-01A1 | 23,740 | - |
| Oral Diseases and Disorders Research | 93.121 | University of Pittsburgh | 1R01DE033322-01 | 333,891 | - |
| NIEHS Superfund Hazardous Substances_Basic Research and Education | 93.143 | University of Louisville | P42ES023716 | 165,627 | - |
| Human Genome Research | 93.172 | | | 7,243,614 | 2,166,885 |
| Human Genome Research | 93.172 | California Institute Of Technology | U24HG00222323 | 29,414 | - |
| Human Genome Research | 93.172 | The Broad Institute Inc | 5U24HG01026206 | 96,787 | - |
| Human Genome Research | 93.172 | University of Pennsylvania | 5R21HG01197902 | 60,808 | - |
| Human Genome Research | 93.172 | University of California, Santa Cruz | 5U01HG01097104 | 781,680 | - |
| Human Genome Research | 93.172 | University Of North Carolina Chapel Hill | 5U24HG00965006 | 69,987 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | | | 5,397,922 | 642,467 |
| Research Related to Deafness and Communication Disorders | 93.173 | Boystown National Research Hospital | 5R01DC01833005 | 21,731 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | East Carolina University | 5R01DC01770202 | 1,608 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | Northeastern University | 7R01DC01950702 | 258,001 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | Ohio State University | 5U01DC01892002 | 135,655 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | University Of Alabama Birmingham | 5R01DC01598005 | (245) | - |
| Research Related to Deafness and Communication Disorders | 93.173 | University Of Iowa | 5R01DC01848803 | 213,106 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | University Of Pittsburgh | 2R0DC01304806A1 | 60,646 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | University Of Pittsburgh | 5R01HD07951208 | 112,626 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | University of Texas at Dallas | 5R01DC01966002 | 15,767 | - |
| Research Related to Deafness and Communication Disorders | 93.173 | University of Utah | 5R01DC01131111 | 104,689 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Research Related to Deafness and Communication Disorders | 93.173 | Vanderbilt University | 2RM1HG009034 | 50,484 | - |
| Research and Training in Complementary and Integrative Health | 93.213 | | | 2,044,870 | 24,817 |
| Research and Training in Complementary and Integrative Health | 93.213 | University of Minnesota | 5U54AT012307-02 | 9,384 | - |
| Research and Training in Complementary and Integrative Health | 93.213 | Yale University | 5R01AT01141902 | 203,699 | - |
| National Center on Sleep Disorders Research | 93.233 | | | 836,052 | - |
| National Center on Sleep Disorders Research | 93.233 | Johns Hopkins University | 3U01HL15056801S1 | 12,530 | - |
| Mental Health Research Grants | 93.242 | | | 43,934,916 | 7,434,161 |
| Mental Health Research Grants | 93.242 | Allen Institute | 1UM1MH13098001 | 157 | - |
| Mental Health Research Grants | 93.242 | Allen Institute | 5UM1MH13098002 | 507,332 | - |
| Mental Health Research Grants | 93.242 | Chapman University | 5P50MH09688908 | 22,956 | - |
| Mental Health Research Grants | 93.242 | Children's Hospital Los Angeles | 7R01MH12146203 | 109,359 | - |
| Mental Health Research Grants | 93.242 | Columbia University | P50MH115843 | 20,942 | - |
| Mental Health Research Grants | 93.242 | Duke University | 1R01MH12983201 | 60,534 | - |
| Mental Health Research Grants | 93.242 | Emory University | 1R56MH12901901A1 | 32,706 | - |
| Mental Health Research Grants | 93.242 | Emory University | 5R01MH11469205 | (39) | - |
| Mental Health Research Grants | 93.242 | EsperImage LLC | 5R41MH13144902 | 221,823 | - |
| Mental Health Research Grants | 93.242 | Harvard University | 5R01MH12949303 | 274,198 | - |
| Mental Health Research Grants | 93.242 | Icahn School Of Medicine At Mount Sinai | 5R01MH13035402 | 19,716 | - |
| Mental Health Research Grants | 93.242 | Mayo Clinic | 5R01MH122258 | 55,870 | - |
| Mental Health Research Grants | 93.242 | Neurolux | 5R44MH114944 | 11,050 | - |
| Mental Health Research Grants | 93.242 | New York University | 5P50MH11366203 | 12,474 | - |
| Mental Health Research Grants | 93.242 | Northwestern University | 3R01M12187704S1 | 58,192 | - |
| Mental Health Research Grants | 93.242 | Northwestern University | 5R01M12187704 | 771,746 | - |
| Mental Health Research Grants | 93.242 | Nous Imaging Inc | 4R44MH12127602 | 247,419 | - |
| Mental Health Research Grants | 93.242 | Nous Imaging Inc | 5R44MH12206603 | 200,140 | - |
| Mental Health Research Grants | 93.242 | Nous Imaging Inc | 5R44MH12456704 | 171,879 | - |
| Mental Health Research Grants | 93.242 | Pennsylvania State University | 1R01MH13000701 | 390,017 | - |
| Mental Health Research Grants | 93.242 | Pennsylvania State University | R56MH126349 | (1,114) | - |
| Mental Health Research Grants | 93.242 | Purdue University | 5R01MH12621302 | 181,864 | - |
| Mental Health Research Grants | 93.242 | Regents Of The University Of Minnesota | 5R01MH09677310 | 435,939 | - |
| Mental Health Research Grants | 93.242 | Regents Of The University Of Minnesota | 5R01MH11696104 | 2,596 | - |
| Mental Health Research Grants | 93.242 | Research Foundation for The State University of New York | 5R34MS12408202 | 12,380 | - |
| Mental Health Research Grants | 93.242 | Rosalind Franklin University of Medicine and Science | 5R01MH13037502 | 83,742 | - |
| Mental Health Research Grants | 93.242 | RTI International | 1R01MH13156501A1 | 32,983 | - |
| Mental Health Research Grants | 93.242 | Rutgers The State University Of NJ | 5U524MH06845720 | 12,388 | - |
| Mental Health Research Grants | 93.242 | The Miriam Hospital | 5R01MH11465705 | (416) | - |
| Mental Health Research Grants | 93.242 | The Regents of the University of California | 5R01MH18221704 | 431,789 | - |
| Mental Health Research Grants | 93.242 | The Regents of the University of California | 5R24MH129166 | 263,963 | - |
| Mental Health Research Grants | 93.242 | The Salk Institute for Biological Studies | UM1MH130994 | 757,334 | - |
| Mental Health Research Grants | 93.242 | Trustees Of Columbia University In the City Of New York | 5K01MH12231903 | 41 | - |
| Mental Health Research Grants | 93.242 | Trustees Of Columbia University In the City Of New York | 5R01MH12059704 | 10,245 | - |
| Mental Health Research Grants | 93.242 | Universidad de O'Higgins | 5U01MH11550204 | (1,637) | - |
| Mental Health Research Grants | 93.242 | Universidad de O'Higgins | 5U01MH11550205 | (7,990) | - |
| Mental Health Research Grants | 93.242 | University Of Alabama Birmingham | 4R33MH127155-03 | 17,054 | - |
| Mental Health Research Grants | 93.242 | University Of California Los Angeles | 5R01MH10002716 | 188,501 | - |
| Mental Health Research Grants | 93.242 | University of Illinois Chicago | 4R33MH119237-02 | 41,735 | - |
| Mental Health Research Grants | 93.242 | University Of Maryland | 1RF1MH12316301A1 | 24,244 | - |
| Mental Health Research Grants | 93.242 | University of Missouri, St. Louis | 5R01MH10855904 | (12,356) | - |
| Mental Health Research Grants | 93.242 | University Of North Carolina Chapel Hill | 1R01MH130441-01A1 | 15,486 | - |
| Mental Health Research Grants | 93.242 | University Of North Carolina Chapel Hill | 5K01MH114721-05 | 33,202 | - |
| Mental Health Research Grants | 93.242 | University of Pennsylvania | 1R01MH13296201A1 | 139,194 | - |
| Mental Health Research Grants | 93.242 | University Of Rochester | 5P50MH106435 | 440,359 | - |
| Mental Health Research Grants | 93.242 | University of Washington | 7P50MH126219-03 | 10,210 | - |
| Mental Health Research Grants | 93.242 | Yale University | 2P30MH062294-21 | 38,275 | - |
| Mental Health Research Grants | 93.242 | Yale University | 5P30MH06229419S1 | 21,233 | - |
| Mental Health Research Grants | 93.242 | Yale University | 5U01MH12463903 | 723,772 | - |
| Alcohol Research Programs | 93.273 | | | 1,827,883 | 78,331 |
| Alcohol Research Programs | 93.273 | Johns Hopkins University | 5R01AA02348305 | (1,245) | - |
| Alcohol Research Programs | 93.273 | RTI International | 1R01AA02704901A1 | 135,957 | - |
| COVID-Alcohol Research Programs | 93.273 | State University Of New York | 1R01AA02991401 | 47,114 | - |
| Alcohol Research Programs | 93.273 | State University Of New York | 5U10AA008401 | 1,206,136 | - |
| Alcohol Research Programs | 93.273 | University of California, San Francisco | 1R01AA031445-01A1 | 6,688 | - |
| Alcohol Research Programs | 93.273 | University Of Iowa | 1R01AA030914-01 | 46,357 | - |
| Alcohol Research Programs | 93.273 | University Of Maryland | 7R01AA02998902 | 30,461 | - |
| Alcohol Research Programs | 93.273 | University of Missouri System | 5R01AA02782403 | 106,509 | - |
| Alcohol Research Programs | 93.273 | University Of North Carolina Chapel Hill | 1R01AA030480-01 | 39,975 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | | | 25,329,181 | 7,700,637 |
| Drug Abuse and Addiction Research Programs | 93.279 | Brandeis University | 2P30DA03577206A1 | 5,019 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | Children's Hospital Los Angeles | 5U01DA03692607 | 641,516 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | George Washington University | 5R01DA054751 | 225,064 | - |
| COVID-Drug Abuse and Addiction Research Programs | 93.279 | Harvard Pilgrim Health Care | 1R01DA05513101 | 67,211 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | Intra-Cellular Therapies Inc | 1UG3DA04769901 | 463,768 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | Massachusetts General Hospital | 5R24DA05198802 | 17,567 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | New York University | 4UH3CA261067-02 | 29,394 | - |
| COVID-Drug Abuse and Addiction Research Programs | 93.279 | New York University | 5U24NS11384401 | 7,775 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Drug Abuse and Addiction Research Programs | 93.279 | Rissana, LLC | 1R44DA055161-01 | 45,644 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | Saint Louis University | 5R01DA04381105 | 29,667 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | The Miriam Hospital | 5R25DA03719007 | 4,937 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | The Regents of the University of California | 1U24DA05532501 | 92,310 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | The Regents of the University of California | 5U24DA04112309 | 25,984 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | The Regents of the University of California | 5U24DA04114708 | 118,782 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | The Regents of the University of California | 5U01DA041089 | 26,202 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | University Of Arkansas | 5R21DA05683502 | 64,717 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | University Of California Los Angeles | 5R01DA05375202 | 898 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | University Of North Carolina Chapel Hill | 5R01DA04787605 | 16,812 | - |
| Drug Abuse and Addiction Research Programs | 93.279 | University of Washington | 1R21DA05672501A1 | 45,406 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | | | 7,965,527 | 238,000 |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Albany Research Institute | 5P41EB01878309 | 413,358 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Boston Children's Hospital | 5R01EB03236602 | 198,199 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Cornell University | 5R01EB02925904 | 81,164 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Cornell University | 2R56EB029259-05 | 50,034 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Duke University | 7R01EB02943102 | 33,130 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Georgia Institute Of Technology | 1R01EB02985201 | 4,856 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | Rice University | 1R21EB033160-01 | 34,182 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | TetraImaging, LLC | 5R43EB02640103 | 241,048 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | University Of Delaware | 5R01EB02757703 | 111,116 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | University of Illinois at Urbana-Champaign | 5R01EB02865203 | 2,121 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | University of Michigan | 5R01EB02207508 | 19,914 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | University of Texas Southwestern | 7R01EB03098702 | 62,448 | - |
| Discovery and Applied Research for Technological Innovations to Improve Human Health | 93.286 | University of Virginia | 1R18EB035019-01 | 89,190 | - |
| Minority Health and Health Disparities Research | 93.307 | | | 3,542,442 | 367,790 |
| Minority Health and Health Disparities Research | 93.307 | Michigan State University | 1R01MD01805101 | 140,585 | - |
| Minority Health and Health Disparities Research | 93.307 | Northwestern University | 5R01MD01174904 | (1,122) | - |
| Minority Health and Health Disparities Research | 93.307 | Rector & Visitors Of The University Of Virginia | 5R01MD00770207 | 38,807 | - |
| Minority Health and Health Disparities Research | 93.307 | University Of Maryland College Park | 1R01MD01843701A1 | 40,936 | - |
| Minority Health and Health Disparities Research | 93.307 | University Of North Carolina Chapel Hill | 1R21MD01646701 | 34,025 | - |
| Minority Health and Health Disparities Research | 93.307 | University Of North Carolina Chapel Hill | 5R01MD015109-04 | 59,179 | - |
| Trans-NIH Research Support | 93.310 | | | 10,071,705 | 1,552,404 |
| COVID-Trans-NIH Research Support | 93.310 | | | 12,042 | |
| Trans-NIH Research Support | 93.310 | Duke University | 3UCOD02337504S1 | 27,019 | - |
| Trans-NIH Research Support | 93.310 | Florida State University | 5R01MD01740403 | 99,964 | - |
| Trans-NIH Research Support | 93.310 | George Mason University | 1OT2OD034479-01 | 49,812 | - |
| Trans-NIH Research Support | 93.310 | George Mason University | 5OT2OD03447902 | 85,128 | - |
| Trans-NIH Research Support | 93.310 | Harvard University | 5U01HG00753008 | (6,181) | - |
| Trans-NIH Research Support | 93.310 | Massachusetts General Hospital | 1UF1NS131791-01 | 58,687 | - |
| Trans-NIH Research Support | 93.310 | Medical College Of Wisconsin | 5U24HG010423-04 | (23) | - |
| Trans-NIH Research Support | 93.310 | Regents Of The University Of Michigan | 3U2CES030116404S1 | (488) | - |
| Trans-NIH Research Support | 93.310 | The Board Of Trustees Of The Leland Stanford Junior University | 1U54HG01272301 | 43,254 | - |
| Trans-NIH Research Support | 93.310 | The Board Of Trustees Of The Leland Stanford Junior University | 5U54HG01272302 | 222,668 | - |
| Trans-NIH Research Support | 93.310 | The Brigham And Women's Hospital Inc | 5UH3OD023268O7 | 63,119 | - |
| Trans-NIH Research Support | 93.310 | The Regents of the University of California | 5UM1HG011585 | 112,626 | - |
| Trans-NIH Research Support | 93.310 | University of Connecticut | 5U01HL15634903 | 5,124 | - |
| Trans-NIH Research Support | 93.310 | University Of Florida | OT2OD033753-01 | 39,607 | - |
| Trans-NIH Research Support | 93.310 | University of Nevada, Las Vegas | 1U01OD03323901 | 1,294 | - |
| Trans-NIH Research Support | 93.310 | University of Nevada, Las Vegas | 8U01HD11525602 | 8,010 | - |
| Trans-NIH Research Support | 93.310 | University Of North Carolina Chapel Hill | 5U24DK116204 | 123,025 | - |
| Trans-NIH Research Support | 93.310 | University of Rwanda | 1UE5HL172181-01 | 15,157 | - |
| Trans-NIH Research Support | 93.310 | University of South Florida | 1OT2OD032720-01 | 177,903 | - |
| Trans-NIH Research Support | 93.310 | University Of Wisconsin | 5UH3OD023282 | 147,387 | - |
| National Center for Advancing Translational Sciences | 93.350 | | | 14,166,553 | 1,440,960 |
| National Center for Advancing Translational Sciences | 93.350 | Altamira Therapeutics Inc | 1R41TR00324401A1 | 68,379 | - |
| National Center for Advancing Translational Sciences | 93.350 | Children's Hospital Corporation | 5U01TR00262303 | 36,212 | - |
| National Center for Advancing Translational Sciences | 93.350 | Dystonia Medical Research Foundation | U54TR001456 | 2,032 | - |
| National Center for Advancing Translational Sciences | 93.350 | Harvard University | 3UL1TR00254104S2 | (3,475) | - |
| National Center for Advancing Translational Sciences | 93.350 | Northwestern University | 1U01TR00352801 | 240,049 | - |
| National Center for Advancing Translational Sciences | 93.350 | Saint Louis Integrated Health Network | 5U01TR003528-03 | 166,895 | - |
| National Center for Advancing Translational Sciences | 93.350 | Seattle Children's Research Institute | 1R21TR00405701 | (4,203) | - |
| National Center for Advancing Translational Sciences | 93.350 | University of California | 1R21TR00442201 | 25,896 | - |
| National Center for Advancing Translational Sciences | 93.350 | University of Colorado Denver | 5U24TR00230606 | 4,726 | - |
| National Center for Advancing Translational Sciences | 93.350 | University Of Iowa | 5R21TR00341002 | 5,234 | - |
| National Center for Advancing Translational Sciences | 93.350 | University Of North Carolina Chapel Hill | 7R21TR00386002 | 63,397 | - |
| National Center for Advancing Translational Sciences | 93.350 | University of Pittsburgh Medical Center | 1U01TR00371901A1 | 12,242 | - |
| National Center for Advancing Translational Sciences | 93.350 | University of Pittsburgh Medical Center | 5U01TR00371902 | 21,262 | - |
| National Center for Advancing Translational Sciences | 93.350 | Virginia Commonwealth University | 5R21TR00318402 | 189 | - |
| Research Infrastructure Programs | 93.351 | | | 3,071,002 | - |
| Research Infrastructure Programs | 93.351 | Cornell University | 5P40OD010964 | 103,650 | - |
| Construction Support | 93.352 | | | 7,972,413 | - |
| 21st Century Cures Act - Beau Biden Cancer Moonshot | 93.353 | | | 7,624,940 | 115,995 |
| 21st Century Cures Act - Beau Biden Cancer Moonshot | 93.353 | Children's Hospital Of Philadelphia (The) | 1U54CA23256801 | 2,214 | - |
| 21st Century Cures Act - Beau Biden Cancer Moonshot | 93.353 | Duke University | 1U2CCA23325401 | 95,066 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| 21st Century Cures Act - Beau Biden Cancer Moonshot | 93.353 | Fred Hutchinson Cancer Center | 6UM1CA15496712 | 39,813 | - |
| 21st Century Cures Act - Beau Biden Cancer Moonshot | 93.353 | Stanford University | 1R01CA28389601 | 79,263 | - |
| Nursing Research | 93.361 | | | 1,053,610 | 472,702 |
| COVID-Nursing Research | 93.361 | | | 490,429 | 102,638 |
| Nursing Research | 93.361 | Emory University | 1K23NR020037 | 243 | - |
| Nursing Research | 93.361 | Trustees Of Columbia University In the City Of New York | 2R01NR01694107 | 56,130 | - |
| Nursing Research | 93.361 | University Of Alabama Birmingham | 1R01NR01941701A1 | 34,692 | - |
| Nursing Research | 93.361 | University Of Alabama Birmingham | 5R01NR020523-02 | 52,907 | - |
| Nursing Research | 93.361 | University of Houston | 1R21NR020379 | 97,388 | - |
| Cancer Cause and Prevention Research | 93.393 | | | 12,466,477 | 1,415,647 |
| Cancer Cause and Prevention Research | 93.393 | Arizona State University | 2U01CA19790206 | 72,543 | - |
| Cancer Cause and Prevention Research | 93.393 | Baylor College of Medicine | 2U19CA20365407 | 109,446 | - |
| Cancer Cause and Prevention Research | 93.393 | Baylor University | 5U19CA20365405 | 32 | - |
| Cancer Cause and Prevention Research | 93.393 | Duke University | 1R35CA26393401 | 12,463 | - |
| Cancer Cause and Prevention Research | 93.393 | Eastern Virginia Medical School | 5R37CA245716-03 | 100,214 | - |
| Cancer Cause and Prevention Research | 93.393 | Kaiser Permanente | 1R01CA26232501 | (13,910) | - |
| Cancer Cause and Prevention Research | 93.393 | Lawrence Berkeley National Laboratory | 2P01CA092584-21 | 64,325 | - |
| Cancer Cause and Prevention Research | 93.393 | Mayo Clinic | 5R01CA23361004 | 134,645 | - |
| Cancer Cause and Prevention Research | 93.393 | Mayo Clinic | 5U01CA19556808 | 92,698 | - |
| Cancer Cause and Prevention Research | 93.393 | Medical University of South Carolina | 1R01CA28216501 | 54,600 | - |
| Cancer Cause and Prevention Research | 93.393 | Medical University of South Carolina | 5R37CA269385-02 | 152,797 | 14,018 |
| Cancer Cause and Prevention Research | 93.393 | Northwestern University | 5R01CA218436 | 13,202 | - |
| Cancer Cause and Prevention Research | 93.393 | Research Institute at Nationwide Children's Hospital | 1R01CA284073-01 | 13,659 | - |
| Cancer Cause and Prevention Research | 93.393 | Rockefeller University | 5P01CA196539 | 332,854 | - |
| Cancer Cause and Prevention Research | 93.393 | St. Jude Children's Research Hospital | 5R37CA27621502 | 217,152 | - |
| Cancer Cause and Prevention Research | 93.393 | The Hospital for Sick Children | 5R01CA25111203 | 21,089 | - |
| Cancer Cause and Prevention Research | 93.393 | Trustees Of The University Of Pennsylvania | 5R01CA17490410 | 7,042 | - |
| Cancer Cause and Prevention Research | 93.393 | University of Colorado | 1R01CA279953-01 | 205,538 | - |
| Cancer Cause and Prevention Research | 93.393 | University of North Carolina at Charlotte | 3U01CA23550703S1 | 84,979 | - |
| Cancer Cause and Prevention Research | 93.393 | University Of North Carolina Chapel Hill | 1R01CA276408-01A1 | 46,187 | - |
| Cancer Cause and Prevention Research | 93.393 | University Of North Carolina Chapel Hill | 5P01CA22559704 | 137,004 | - |
| Cancer Cause and Prevention Research | 93.393 | University Of North Carolina Chapel Hill | 7R03CA27248503 | 7,684 | - |
| Cancer Cause and Prevention Research | 93.393 | University Of Texas MD Anderson Cancer Center | 5R01CA22564703 | 367 | - |
| Cancer Cause and Prevention Research | 93.393 | University of Utah | 5U01CA206110 | 204,007 | - |
| Cancer Cause and Prevention Research | 93.393 | University of Washington | 7R01CA26232503 | 75,362 | - |
| Cancer Cause and Prevention Research | 93.393 | Vanderbilt University Medical Center | 5R01CA22500506 | 9,011 | - |
| Cancer Cause and Prevention Research | 93.393 | Wake Forest University | 5R01CA22607806 | 237,070 | - |
| Cancer Detection and Diagnosis Research | 93.394 | | | 16,340,924 | 3,233,974 |
| Cancer Detection and Diagnosis Research | 93.394 | Acoustic Range Estimates LLC | 5R44CA24376403 | 64,985 | - |
| Cancer Detection and Diagnosis Research | 93.394 | Indiana University | 1U24CA27962901A1 | 77,759 | - |
| Cancer Detection and Diagnosis Research | 93.394 | Memorial Sloan Kettering Cancer Center | 5R01CA24423303 | 101,353 | - |
| Cancer Detection and Diagnosis Research | 93.394 | New York University | 5U24CA210972 | (102) | - |
| Cancer Detection and Diagnosis Research | 93.394 | Princeton University | 1U24CA26402701 | (2,865) | - |
| Cancer Detection and Diagnosis Research | 93.394 | Regents Of The University Of Michigan | 5R01CA240706 | 21,725 | - |
| Cancer Detection and Diagnosis Research | 93.394 | Sarya LLC | 1R42CA25779701 | 259,825 | - |
| Cancer Detection and Diagnosis Research | 93.394 | St. Jude Children's Research Hospital | 4U01CA246570-02 | 6,854 | - |
| Cancer Detection and Diagnosis Research | 93.394 | Texas A&M University | 1R21CA26909902 | 76,408 | - |
| Cancer Detection and Diagnosis Research | 93.394 | Trustees Of The University Of Pennsylvania | 5R01CA25871704 | 70,249 | - |
| Cancer Detection and Diagnosis Research | 93.394 | University Of California Los Angeles | 5R01CA24630403 | 10,659 | - |
| Cancer Detection and Diagnosis Research | 93.394 | University Of Florida | 1R01CA27781701A1 | 77,890 | - |
| Cancer Detection and Diagnosis Research | 93.394 | University Of Miami | 5U01CA233363 | 44,703 | - |
| Cancer Detection and Diagnosis Research | 93.394 | University Of San Francisco | 5R01CA21214805 | (3,600) | - |
| Cancer Detection and Diagnosis Research | 93.394 | University of South Florida | 1R01CA240319-01A1 | 17,084 | - |
| Cancer Detection and Diagnosis Research | 93.394 | University of Texas Southwestern | R01CA260855 | 87,643 | - |
| Cancer Treatment Research | 93.395 | | | 12,391,161 | 1,081,525 |
| Cancer Treatment Research | 93.395 | Accuronix Therapeutics | 2R41CA23985302A1 | 34,489 | - |
| Cancer Treatment Research | 93.395 | Accuronix Therapeutics | 5R42CA23985303 | (6,458) | - |
| Cancer Treatment Research | 93.395 | Albert Einstein College of Medicine | 7R01CA235622-05 | 151,963 | - |
| Cancer Treatment Research | 93.395 | American College of Radiology | 1U24CA180803 | 27,307 | - |
| Cancer Treatment Research | 93.395 | Children's Hospital Of Philadelphia (The) | 5R01CA21199602 | 2,054 | - |
| Cancer Treatment Research | 93.395 | Duke University | 3UM1CA18670405S1 | 213,679 | - |
| Cancer Treatment Research | 93.395 | ECOG-ACRIN Cancer Research Group | 5U01CA18082008 | 6,644 | - |
| Cancer Treatment Research | 93.395 | ECOG-ACRIN Cancer Research Group | 5U10CA18082009 | 18,445 | - |
| Cancer Treatment Research | 93.395 | ECOG-ACRIN Cancer Research Group | PDS137629 | 3,864 | - |
| Cancer Treatment Research | 93.395 | George Washington University | 1R01CA27590401 | 321,528 | - |
| Cancer Treatment Research | 93.395 | Memorial Sloan Kettering Cancer Center | 5U01CA23844402 | 40,063 | - |
| Cancer Treatment Research | 93.395 | NRG Oncology Foundation Inc | U10CA180868 | 56,371 | 8,433 |
| Cancer Treatment Research | 93.395 | NRG Oncology Foundation Inc | 5U10CA18086809 | 15,006 | - |
| Cancer Treatment Research | 93.395 | NRG Oncology Foundation Inc | U10CA180868-10 | 7,169 | - |
| Cancer Treatment Research | 93.395 | Public Health Institute | 3U10CA180886-10S1 | 283 | - |
| Cancer Treatment Research | 93.395 | Public Health Institute | 5UM1CA22882305 | 909 | - |
| Cancer Treatment Research | 93.395 | Public Health Institute | 7U10CA18088608 | (1,462) | - |
| Cancer Treatment Research | 93.395 | Public Health Institute | 7UM1CA22882304 | 85,176 | - |
| Cancer Treatment Research | 93.395 | Public Health Institute | U10CA180886 | 172,989 | - |
| Cancer Treatment Research | 93.395 | Regents Of The University Of Minnesota | P01CA111412 | 79,289 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Cancer Treatment Research | 93.395 | Saint Louis University | 1R21CA263428-01A1 | 13,192 | - |
| Cancer Treatment Research | 93.395 | St. Jude Children's Research Hospital | 1U01CA24657001A1 | 3,884 | - |
| Cancer Treatment Research | 93.395 | The Brigham And Women's Hospital Inc | 3U10CA180821-10S1 | 33,292 | - |
| Cancer Treatment Research | 93.395 | The Brigham And Women's Hospital Inc | 5U01CA180821 | 117,017 | - |
| Cancer Treatment Research | 93.395 | Children's Hospital Of Philadelphia (The) | U10CA180886 | (5,395) | - |
| Cancer Treatment Research | 93.395 | The Emmes Company, LLC | 5UM1CA121947 | 346,927 | - |
| Cancer Treatment Research | 93.395 | University Of Cincinnati | 7UG1CA23333805 | 148,732 | - |
| Cancer Treatment Research | 93.395 | University Of Miami | 7R01CA25398602 | 55,776 | - |
| Cancer Treatment Research | 93.395 | University Of Rochester | 1R01CA21489001A1 | (8,164) | - |
| Cancer Treatment Research | 93.395 | University Of Texas MD Anderson Cancer Center | 5R01CA23562204 | (9,533) | - |
| Cancer Treatment Research | 93.395 | Yale University | UM1CA186689 | 438,335 | - |
| Cancer Biology Research | 93.396 | | | 12,762,830 | 567,346 |
| Cancer Biology Research | 93.396 | Case Western Reserve University | 1P01CA245705 | 459,641 | - |
| Cancer Biology Research | 93.396 | Coriell Institute for Medical Research | 5R01CA24423602 | 254,605 | - |
| Cancer Biology Research | 93.396 | Ohio State University | 5P01CA100730 | 681,201 | - |
| Cancer Biology Research | 93.396 | Pennsylvania State University | 5R21CA274265-02 | 96,913 | - |
| Cancer Biology Research | 93.396 | Saint Louis University | 1R37CA265877-01A1 | 59,759 | - |
| Cancer Biology Research | 93.396 | Saint Louis University | 5R37CA26587702 | 44,580 | - |
| Cancer Biology Research | 93.396 | The Board Of Trustees Of The Leland Stanford Junior University | 5R01CA25838403 | 268,402 | - |
| Cancer Biology Research | 93.396 | The Regents of the University of California | 1U01CA26703101 | 33 | - |
| Cancer Biology Research | 93.396 | The Regents of the University of California | 1U01CA26703102 | 43,869 | - |
| Cancer Biology Research | 93.396 | The Regents of the University of California | 5U01CA26703103 | 120,047 | - |
| Cancer Biology Research | 93.396 | University of California, San Francisco | 7R01CA23455305 | 114,895 | - |
| Cancer Center Support Grants | 93.397 | | | 13,473,513 | 1,136,545 |
| Cancer Center Support Grants | 93.397 | Northwestern University | 5P50CA221747-05 | 7,245 | - |
| Cancer Center Support Grants | 93.397 | St. Jude Children's Research Hospital | 3P30CA021765445S2 | 14,844 | - |
| Cancer Center Support Grants | 93.397 | University Of Alabama Birmingham | 5R01MD010441-05 | 8,306 | - |
| Cancer Center Support Grants | 93.397 | University Of North Carolina Chapel Hill | 1P50CA257911-01A1 | 80,533 | - |
| Cancer Research Manpower | 93.398 | | | 5,515,144 | - |
| Cancer Control | 93.399 | | | 165,560 | - |
| Cancer Control | 93.399 | University of Michigan | 5UG1CA242632 | 15,523 | - |
| Cardiovascular Diseases Research | 93.837 | | | 33,347,943 | 3,403,543 |
| Cardiovascular Diseases Research | 93.837 | Beth Israel Deaconess Medical Center | 1R01HL16456101 | 34,141 | - |
| Cardiovascular Diseases Research | 93.837 | Cedars Sinai Medical Center | 5R01HL14994604 | 4,073 | - |
| Cardiovascular Diseases Research | 93.837 | Clemson University | 2RO1HL133662-05A1 | 130,936 | - |
| Cardiovascular Diseases Research | 93.837 | Duke University | 1OT2HL156812-01 | 4,481 | - |
| Cardiovascular Diseases Research | 93.837 | Duke University | 1R01HL15539601A1 | 13,056 | - |
| Cardiovascular Diseases Research | 93.837 | Emory University | 5R01HL12239207 | (24) | - |
| Cardiovascular Diseases Research | 93.837 | HealthCore Inc | U24HL135691 | (11,461) | - |
| Cardiovascular Diseases Research | 93.837 | Indiana University | 1R01HL1592160lA1 | 11,181 | - |
| COVID-Cardiovascular Diseases Research | 93.837 | Johns Hopkins University | 10T2HL15681201 | 7,200 | - |
| Cardiovascular Diseases Research | 93.837 | Johns Hopkins University | 5U01HL09681212 | 429,803 | - |
| Cardiovascular Diseases Research | 93.837 | National Marrow Donor Program | 1U24HL138660 | 171 | - |
| Cardiovascular Diseases Research | 93.837 | New England Research Institutes | 5U24HL135691 | 7,046 | - |
| Cardiovascular Diseases Research | 93.837 | New York University | 2U01HL09681213 | 191,194 | - |
| Cardiovascular Diseases Research | 93.837 | New York University | 5R01HL04509532 | 361,492 | - |
| Cardiovascular Diseases Research | 93.837 | New York University | 5R01HL147811 | 27,723 | - |
| Cardiovascular Diseases Research | 93.837 | New York University | 5R01HL157091-03 | 46,068 | - |
| Cardiovascular Diseases Research | 93.837 | Ohio State University | 5R01HL14858104 | 24,452 | - |
| Cardiovascular Diseases Research | 93.837 | Rector & Visitors Of The University Of Virginia | 5P01HL12084009 | 607,089 | - |
| Cardiovascular Diseases Research | 93.837 | Regents Of The University Of Michigan | 4UH3HL15913402 | 23,563 | - |
| Cardiovascular Diseases Research | 93.837 | Saint Louis University | 1R01HL160553-01A1 | 72,128 | - |
| Cardiovascular Diseases Research | 93.837 | Saint Louis University | R56HL165199 | 25,874 | - |
| Cardiovascular Diseases Research | 93.837 | State University Of New York | 1R01HL16662801A1 | 155,559 | - |
| Cardiovascular Diseases Research | 93.837 | State University Of New York | 5U01HL13155205 | 3,374 | - |
| Cardiovascular Diseases Research | 93.837 | Trustees Of The University Of Pennsylvania | 5R34HL14692703 | (1,681) | - |
| Cardiovascular Diseases Research | 93.837 | UNandUP, LLC (UN&UP) | 2R44HL147745-02A1 | 27,115 | - |
| Cardiovascular Diseases Research | 93.837 | University Of Alabama Birmingham | 2R01HL12033807A1 | 34,312 | - |
| Cardiovascular Diseases Research | 93.837 | University Of Alabama Birmingham | 5R01HL12033809 | 36,686 | - |
| Cardiovascular Diseases Research | 93.837 | University Of Alabama Birmingham | 5R01HL148462-04 | 37,844 | - |
| Cardiovascular Diseases Research | 93.837 | University Of California Davis | 5UH3HL1418002 | 2,392 | - |
| Cardiovascular Diseases Research | 93.837 | University Of Iowa | 1R01HL171624-01 | 23,479 | - |
| Cardiovascular Diseases Research | 93.837 | University Of North Carolina Chapel Hill | 5R01HL15725502 | 25,750 | - |
| Cardiovascular Diseases Research | 93.837 | University of Pennsylvania School of Medicine | 5R01HL14827203 | 64,336 | - |
| Cardiovascular Diseases Research | 93.837 | University of Pittsburgh Medical Center | 7R01HL15946102 | 56,243 | - |
| Cardiovascular Diseases Research | 93.837 | University of Texas Health Science Center at Houston | 5R01HL14502503 | 37,264 | - |
| Cardiovascular Diseases Research | 93.837 | University of Texas Health Science Center at Houston | 5R01HL14686003 | 30,392 | - |
| Cardiovascular Diseases Research | 93.837 | University of Washington | 5P01HL15132803 | 398,116 | - |
| Cardiovascular Diseases Research | 93.837 | University of Washington | 5R01HL16182902 | 31,625 | - |
| Lung Diseases Research | 93.838 | | | 9,196,700 | 581,230 |
| Lung Diseases Research | 93.838 | Boston University | 1P01HL170952-01 | 2,380 | - |
| Lung Diseases Research | 93.838 | Children's Hospital Of Philadelphia (The) | 5R01HL14805404 | 5,430 | - |
| Lung Diseases Research | 93.838 | Cornell University | 1UG3HL15494401A1 | 8,258 | - |
| Lung Diseases Research | 93.838 | Fred Hutchinson Cancer Center | 5UH3HL14701104 | 11,107 | - |
| Lung Diseases Research | 93.838 | Fred Hutchinson Cancer Center | 6UH3HL14701103 | (14,014) | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Lung Diseases Research | 93.838 | Northwestern University | 5P01HL15499803 | 54,535 | - |
| Lung Diseases Research | 93.838 | Ohio State University | SPC-1000012331 / GR130859 | 629,527 | - |
| Lung Diseases Research | 93.838 | Rector & Visitors Of The University Of Virginia | R01HL157407 | 27,422 | - |
| Lung Diseases Research | 93.838 | Regents Of The University Of Michigan | 1R01HL15351901 | 865 | |
| Lung Diseases Research | 93.838 | Regents Of The University Of Michigan | 5R01HL14726104 | 98,520 | - |
| Lung Diseases Research | 93.838 | The Brigham And Women's Hospital Inc | 5U01HL14600204 | 74,216 | - |
| Lung Diseases Research | 93.838 | The Regents of the University of California | OT2HL16184701 | 244,754 | - |
| COVID-Lung Diseases Research | 93.838 | Trustees Of Columbia University In the City Of New York | RTI2231202175716617 8 | 28,335 | - |
| Lung Diseases Research | 93.838 | Trustees Of The University Of Pennsylvania | 4UH3HL15230502 | 8,179 | - |
| Lung Diseases Research | 93.838 | Trustees Of The University Of Pennsylvania | 5U01HL148857 | 131,474 | - |
| Lung Diseases Research | 93.838 | University of Alabama | 5R01HL147603-04 | 13,860 | - |
| Lung Diseases Research | 93.838 | University Of Arizona | 5U01HL13004506 | 320,385 | 20,677 |
| Lung Diseases Research | 93.838 | University Of Arizona | R25-HL126140 | 7,933 | - |
| Lung Diseases Research | 93.838 | University Of Cincinnati | 1R01HL16226101A1 | 6,174 | - |
| Lung Diseases Research | 93.838 | University of Colorado Denver | 5P01HL15296104 | 14,920 | - |
| Lung Diseases Research | 93.838 | University Of North Carolina Chapel Hill | 5U24HL13899806 | 299,371 | - |
| Lung Diseases Research | 93.838 | University Of North Carolina Chapel Hill | 5U54HL096458 | 71,313 | - |
| Lung Diseases Research | 93.838 | University of Pittsburgh | 5R01HL142084-04 | 11,958 | - |
| Lung Diseases Research | 93.838 | University of Pittsburgh | 1R01HL166953-01A1 | 15,008 | - |
| Lung Diseases Research | 93.838 | University of Washington | 1R03HL16025101A1 | 13,497 | - |
| Lung Diseases Research | 93.838 | Vanderbilt University Medical Center | 1U01HL168412-01 | 16,755 | - |
| Lung Diseases Research | 93.838 | Wayne State University | 5R01HL148247 | 59,838 | - |
| Lung Diseases Research | 93.838 | Weill Medical College of Cornell University | 4R33 HL15301102 | 133,892 | - |
| Blood Diseases and Resources Research | 93.839 | | | 9,272,885 | 659,006 |
| Blood Diseases and Resources Research | 93.839 | Emory University | 5UG3HL148560 | 69,921 | - |
| Blood Diseases and Resources Research | 93.839 | Icahn School Of Medicine At Mount Sinai | 1U01HL16703601 | 80,962 | - |
| Blood Diseases and Resources Research | 93.839 | Medical College Of Wisconsin | 1U01HL15985001 | (5,258) | - |
| Blood Diseases and Resources Research | 93.839 | National Marrow Donor Program | 1U24HL15756001A1 | 16 | - |
| Blood Diseases and Resources Research | 93.839 | National Marrow Donor Program | 5U24HL138660 | 17,319 | - |
| Blood Diseases and Resources Research | 93.839 | Nemours Foundation | 7U01HL159850-03 | 15,158 | - |
| Blood Diseases and Resources Research | 93.839 | New York University | 1UG3HL15579801A1 | 5,497 | - |
| Blood Diseases and Resources Research | 93.839 | New York University | 4UG3HL15579802 | 55,079 | - |
| Blood Diseases and Resources Research | 93.839 | Senseion Therapeutics, Inc. | 1R44HL169181-01A1 | 4,548 | - |
| Blood Diseases and Resources Research | 93.839 | University Of Alabama Birmingham | 1UG3HL157401-01A1 | 2,634 | - |
| Blood Diseases and Resources Research | 93.839 | University of Colorado Denver | R33HL141794 | 98,966 | - |
| Blood Diseases and Resources Research | 93.839 | University Of Maryland | 7UH3HL14319205 | 41,487 | - |
| Blood Diseases and Resources Research | 93.839 | Versiti Wisconsin Inc | 5P01HL14445704 | 536,111 | - |
| Blood Diseases and Resources Research | 93.839 | Versiti Wisconsin Inc | 5R01HL06883515 | 11,284 | - |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | | | 4,348,631 | 1,015,728 |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | Infectious Diseases Research Collaboration | 3UH3HL154501-04S1 | 9,018 | - |
| COVID-Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | New York University | 0T2HL156812 | 960 | - |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | Universidad Peruana Cayetano Heredia | 5UGHL15237102 | 169,927 | - |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | Universidad Peruana Cayetano Heredia | 5UGHL15237103 | 16 | - |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | University of Abuja | 1UG3HL154498-04 | 41,038 | - |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | University of Abuja | 4UG3HL15238103 | 56,224 | - |
| Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders | 93.840 | Vanderbilt University | 1OT2HL15681201 | 131,493 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | | | 14,659,520 | 1,077,317 |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Biorestorative Therapies Inc | 1R41AR0793401 | 2,730 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Boston University | 5R01AR07442804 | 3,934 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Children's Hospital Of Philadelphia (The) | 1R01AR07982201 | 4,947 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Cleveland Clinic Lerner College of Medicine | 3R01AR07542204S1 | 34,131 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Hebrew Rehabilitation Center | 5R01AR07534602 | 16,307 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Icahn School Of Medicine At Mount Sinai | 5R01AR07700703 | 24,017 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Indiana University | 5R01AR07647702 | 10,502 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Massachusetts General Hospital | 5R01AR07601304 | 17,871 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Northeast Ohio Medical University | 5R01AR07776202 | (762) | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Regents Of The University Of Michigan | 5R01AR07936702 | 139,119 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Rush University Medical Center Obligated Group | 5P30AR079206-02 | 15,053 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | St. Louis University | A01883-17749 | 255,095 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | The Brigham And Women's Hospital Inc | 5R01AR05555712 | 21,197 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | The Brigham And Women's Hospital Inc | U01AR070498 | 1,061 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Trustees Of Columbia University In the City Of New York | 5R01AR06294709 | 121,460 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | University Of California Irvine | 1R01AR078340 | 62,708 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | University Of Pittsburgh | 5R01AR07614604 | 51,620 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | University Of Texas Southwestern Medical Center | 1R01AR078311-01A1 | 18,888 | - |
| Arthritis, Musculoskeletal and Skin Diseases Research | 93.846 | Vanderbilt University | 5R01AR06084608 | 110,592 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | | | 51,080,550 | 6,136,962 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Acetaminophen Toxicity Diagnostics LLC | 5SB1DK079387 | 2,876 | - |
| COVID-Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Albert Einstein College of Medicine | P30DK020541 | 171,644 | 61,525 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Ann & Robert H. Lurie Children's Hospital of Chicago | U01DK127995 | 5,977 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Augusta University | 5U24DK11525504 | (22,027) | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Beckman Research Institute of the City of Hope | U24DK104162-09 | 212,268 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Case Western Reserve University | U01DK094157 | 141,156 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Cedars Sinai Medical Center | 5U01DK06241320 | (1,166) | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Children's Hospital Of Philadelphia (The) | 5R01DK09783007 | 30,361 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Children's Mercy Kansas City | 5U01DK06614322 | 646 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Cleveland Clinic Lerner College of Medicine | 5R01DK12279002 | 295,300 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | George Washington University | 5U01DK09824610 | 29,968 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Georgia Institute Of Technology | R01DK133702 | 97,557 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Icahn School Of Medicine At Mount Sinai | 1R01DK135470-01 | 6,735 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Johns Hopkins University | 5R01DK128900-04 | 5,389 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | McGill University | 5R01DK11073703 | 950 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Nationwide Children's Hospital | 5U01DK10086609 | 24,848 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | NorthShore University HealthSystem | 2R01DK100368-06A1 | 15,918 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Northern California Institute For Research And Education | 5R01DK125646 | 38,918 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Northwestern University | 1R01DK134629-01 | 36,474 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Northwestern University | 2R01DK09221709 | 71,191 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Northwestern University | 5R01DK12574902 | 6,825 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Oregon Health & Science University | 5R01DK11549505 | 104 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | PlatformSTL | 1R41DK135161-01 | 67,555 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | PlatformSTL | 5R42DK12025303 | 25,267 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Rutgers The State University Of NJ | 1R01DK13288501 | 68,218 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Saint Louis University | 1R01DK13453102 | 18,179 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Senseion Therapeutics, Inc. | 2R44DK12159802A1 | 109,369 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Senseion, LLC | 5R44DK12660003 | 143,373 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | The Board Of Trustees Of The Leland Stanford Junior University | 1K12DK13399501 | 160,233 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | The Brigham And Women's Hospital Inc | 1U24DK135157-01 | 127,774 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | The Children's Mercy Hospital | 5U01DK06614320 | 4,106 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Alabama Birmingham | 5P30DK07933715 | 3,165 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Alabama Birmingham | 5R01DK12749702 | 777 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of California, Los Angeles | 5U01DK122013-03 | 1,610 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of California, San Francisco | 5R01DK11598703 | 10,615 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of California, San Francisco | 5R01DK12279704 | 18,056 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Chicago | 5U54DK11861205 | 214,177 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of Colorado Denver | 1U01DK12919102 | 9,135 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Florida | 7R01DK114485-05 | 2,530 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Iowa | 3U01DK108334-08S1 | 124 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Iowa | 3U01DK10833409S1 | 2,239 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Iowa | 5R01DK11875204 | 17,779 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Iowa | 5U01DK10833407 | 43,015 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of Kansas Medical Center | 1R01DK134737-01 | 30,415 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of Kansas Medical Center | 1R56DK12923401 | 423,514 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University of Maryland, Baltimore | 5U24DK126110 | 77,365 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Tennessee | 7R01DK12574904 | 2,971 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | University Of Wisconsin | 1U24DK127726-01 | 22,422 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Vanderbilt University Medical Center | 1R01DK11921201 | (1,335) | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Wake Forest University | 5R01DK12887104 | 33,640 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | Weill Medical College of Cornell University | 5R01DK12581702 | 3,961 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | | 54,073,467 | 5,860,049 |
| COVID-Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | | 68,073 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Albany Research Institute | 7U01NS10891603 | 116,776 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Barrow Neurological Institute | 1OT2NS13693901 | 195,553 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Beth Israel Deaconess Medical Center | 1R21NS12721101A1 | 3,190 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Beth Israel Deaconess Medical Center | 5R01NS118146604 | 14,848 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Beth Israel Deaconess Medical Center | 5R21NS12721102 | 10,231 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Beth Israel Deaconess Medical Center | 7R01NS118146603 | 33,249 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | California Institute Of Technology | 1U01NS12656201 | 248,149 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Children's National Health System | 5R01NS11229405 | 27,521 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Cleveland Clinic Foundation | U01NS116776 | 44,930 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Duke University | 5R01NS11158803 | 399 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Emory University | 5U54NS11602510 | 354,725 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | FreeFlow Medical Device LLC | 5R42NS10370404 | 131,439 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Harvard University | 1U2CNS13241501 | 893,786 | 403,663 |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Harvard University | 3U2CNS132415-01S1 | 271,394 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Hugo W Moser Research Institute at Kennedy Krieger Inc | 2K12NS09848206 | 466,541 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Icahn School Of Medicine At Mount Sinai | 5R01NS12744202 | 27,586 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Johns Hopkins University | 5R01NS10629202 | 571 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Johns Hopkins University | 5U01NS11167803 | 50,353 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Massachusetts General Hospital | 5R01NS117609-03 | 45,915 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Massachusetts General Hospital | 5RO1NS11102905 | 61,995 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Massachusetts General Hospital | 7R01NS112712-04 | 39,847 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Mayo Clinic | 1U01NS128612-01 | 114,043 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Mayo Clinic | 5U01NS128612-02 | 213,976 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Medical University of South Carolina | 3OT2NS129366-01S1 | 24,307 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Minnetronix | 5R44NS11024703 | (19,649) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Mitochondria in Motion Inc | 2R42NS11364201 | 111,909 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Mitochondria in Motion Inc | 5R42NS11518403 | 57,528 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Northwestern University | 5R01NS12586302 | 59,715 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Northwestern University | 5U01NS11385102 | 32,388 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Nous Imaging Inc | 1R44NS12952101 | 104,447 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Ohio State University | 1R01NS12368701 | 12,276 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Oregon Health & Science University | 1015486_WUSTL | 158,801 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Phoenix Nest Inc | 2U44NS08906105 | (24) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Rector & Visitors Of The University Of Virginia | 5R01NS09911804 | (29) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Rector & Visitors Of The University Of Virginia | 5R01NS12567702 | 250,949 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Regents Of The University Of Colorado | 1U01NS11431201A1 | 12,420 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Regents Of The University Of Michigan | 1RF1NS127606-01 | 20,637 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Research Foundation of the City University of New York | 5R01NS11801203 | 17,529 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Rutgers The State University Of NJ | U24NS095914 | 183,110 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Saint Louis University | 5R01NS11428904 | 17,437 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | St. Jude Children's Research Hospital | 5R01NS12111403 | 436,339 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | St. Louis College of Pharmacy | 1R34NS126036-01 | 1,124 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | St. Louis College of Pharmacy | 5R01NS12307002 | 38,546 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | The Board Of Trustees Of The Leland Stanford Junior University | 5R01NS12172002 | 8,514 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | The Broad Institute Inc | 1U24NS132940-01 | 61,035 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of Columbia University In the City Of New York | 1R01NS11082601A1 | (291) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of Columbia University In the City Of New York | 5R01NS11082603 | 55,097 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of The University Of Pennsylvania | 1U19NS11045601A1 | (13,204) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of The University Of Pennsylvania | 2-RF1-NS-103873-05 | 55,326 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of The University Of Pennsylvania | 582577 | 57,415 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of The University Of Pennsylvania | 5R01NS11586902S1 | (10,984) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Trustees Of The University Of Pennsylvania | 5U19NS110456 | 1,030,624 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | UNandUP, LLC (UN&UP) | 1R44NS12260401 | 5,413 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | UNandUP, LLC (UN&UP) | 1R44NS13260501 | 35,253 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Arizona | 5R01NS10629805 | 8,963 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Arizona | 5R01NS12710802 | 83,476 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of California Davis | 75N94020D00002 | 17,673 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of California Irvine | 1R01NS123287-01A1 | 199,305 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of California, San Francisco | 1U01NS12083601 | (1,503) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of California, San Francisco | 1U54NS12398501 | 210,196 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of California, San Francisco | 5R01NS058721-13 | 43,054 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of California, San Francisco | 5R01NS111166-03 | 19,337 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of California, San Francisco | 5U01NS12083603 | 183,629 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of California, San Francisco | 5U54NS123985-03 | 624,763 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Chicago | 5R01NS11626202 | 139,808 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 1UG3NS119702-01A1 | 6,039 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 1U01NS10228901A1 | 9,437 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 1U01NS11072801 | 289 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 1U01NS11077201 | 33,267 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 1U01NS117450-01A1 | 34,898 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 1UG3NS125023-01A1 | 10,007 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 5U01NS09904302 | 42,108 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 5U01NS10651302 | 14,875 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Cincinnati | 7U01NS10069903 | 3,029 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of Connecticut | 5R01NS10263306 | (224) | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Florida | 5U01NS11956203 | 5,931 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of Illinois Chicago | 1R01NS127403-01A1 | 145,622 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Miami | 1U24NS12085801 | 99,665 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of North Carolina Chapel Hill | 5R01NS12223002 | 154,253 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Pittsburgh | 1R01NS129613-01A1 | 11,842 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Southern California | 5R01NS03446724 | 202,475 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University Of Southern California | 5UH3NS11692904 | 128,695 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of Texas Medical Branch | 1U3NS128397-01A1 | 2,157 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of Utah | 5U01NS107486 | 50,352 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of Washington | 1U01NS128537-01 | 93,080 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | University of Washington | 5R01NS091618-09 | 64,589 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Vanderbilt University | 5UH3NS116218-03 | 58,200 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Virginia Commonwealth University | 1U01NS12497401A1 | 39,897 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Weill Medical College of Cornell University | 1R01NS13011301 | 38,296 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Weill Medical College of Cornell University | 5R01NS11199703 | 192,231 | - |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | Yale University | 1UG3NS130228-01 | 52,598 | - |
| Allergy and Infectious Diseases Research | 93.855 | | | 75,656,694 | 12,291,739 |
| COVID-Allergy and Infectious Diseases Research | 93.855 | | | 755,817 | |
| Allergy and Infectious Diseases Research | 93.855 | Albert Einstein College of Medicine | 5R01AI15819403 | 400,517 | - |
| Allergy and Infectious Diseases Research | 93.855 | Baylor College of Medicine | 2R01AI03295630 | (27) | - |
| Allergy and Infectious Diseases Research | 93.855 | Baylor College of Medicine | 5U19AI157981-03 | 10,654 | - |
| Allergy and Infectious Diseases Research | 93.855 | Benaroya Research Institute At Virginia Mason | 5U19AI6789102 | 294,226 | - |
| Allergy and Infectious Diseases Research | 93.855 | Benaroya Research Institute At Virginia Mason | UM1AI109565 | 241,329 | - |
| Allergy and Infectious Diseases Research | 93.855 | Big Eye Diagnostics | 1R43AI17245901 | 7,913 | - |
| Allergy and Infectious Diseases Research | 93.855 | Boston Children's Hospital | 1R56AI16301301 | 656 | - |
| Allergy and Infectious Diseases Research | 93.855 | Boston University | 1R21AI15623601 | 14,583 | - |
| Allergy and Infectious Diseases Research | 93.855 | Cedars Sinai Medical Center | 1U01AI17042402 | 53,689 | - |
| Allergy and Infectious Diseases Research | 93.855 | Children's Hospital Corporation | 5R01AI17314202 | 8,132 | - |
| Allergy and Infectious Diseases Research | 93.855 | Children's Hospital Corporation | 5U01AI12661406 | 152,029 | - |
| Allergy and Infectious Diseases Research | 93.855 | Children's Hospital Los Angeles | 1U01AI12661201A1 | 3,843 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Allergy and Infectious Diseases Research | 93.855 | Children's Hospital Of Philadelphia (The) | 5R01AI17151402 | 187,320 | - |
| Allergy and Infectious Diseases Research | 93.855 | Cleveland Clinic Lerner College of Medicine | 7R01AI12777406 | 2,252 | - |
| Allergy and Infectious Diseases Research | 93.855 | Duke University | 7R01-AI125045-08 | (25) | - |
| Allergy and Infectious Diseases Research | 93.855 | Duke University | 5U01-AI163065-03 | 60,421 | - |
| Allergy and Infectious Diseases Research | 93.855 | Duke University | 5R01AI14582805 | 254,952 | - |
| Allergy and Infectious Diseases Research | 93.855 | Duke University | 5U01AI16309903 | 56,629 | - |
| Allergy and Infectious Diseases Research | 93.855 | Emory University | 1R21AI173471-01A1 | 33,341 | - |
| Allergy and Infectious Diseases Research | 93.855 | Emory University | 1U01AI15074701 | (512) | - |
| Allergy and Infectious Diseases Research | 93.855 | Emory University | 5U01AI15074704 | 241,377 | - |
| Allergy and Infectious Diseases Research | 93.855 | Emory University | 5U19AI11048310 | 178,639 | - |
| Allergy and Infectious Diseases Research | 93.855 | Family Health International | UM1AI068619 | 86,313 | - |
| Allergy and Infectious Diseases Research | 93.855 | Fimbrion Therapeutics Inc | 1R43AI17255901A1 | 85,983 | - |
| Allergy and Infectious Diseases Research | 93.855 | Fimbrion Therapeutics Inc | 5R44AI14983304 | 323,919 | - |
| Allergy and Infectious Diseases Research | 93.855 | Florida State University | 5R01AI173416-03 | 14,373 | - |
| Allergy and Infectious Diseases Research | 93.855 | Florida State University | 5R21AI178556-03 | 23,313 | - |
| Allergy and Infectious Diseases Research | 93.855 | Forward Defense LLC | 1R41AI16713701A1 | 3,976 | - |
| Allergy and Infectious Diseases Research | 93.855 | Fox Chase Cancer Center | 1R56AI15096501A1 | 4,768 | - |
| Allergy and Infectious Diseases Research | 93.855 | Fox Chase Cancer Center | 1R56AI16808701A1 | 239,664 | - |
| Allergy and Infectious Diseases Research | 93.855 | Icahn School Of Medicine At Mount Sinai | 1P01AI172531-01 | 517,195 | - |
| Allergy and Infectious Diseases Research | 93.855 | Icahn School Of Medicine At Mount Sinai | 1R01AI168178-01 | 167,550 | - |
| Allergy and Infectious Diseases Research | 93.855 | Icahn School Of Medicine At Mount Sinai | 5R01AI16817802 | 281,405 | - |
| Allergy and Infectious Diseases Research | 93.855 | Icahn School Of Medicine At Mount Sinai | 5R21AI16704703 | 3,373 | - |
| Allergy and Infectious Diseases Research | 93.855 | Johns Hopkins University | 2P30AI09418911 | 64,127 | - |
| Allergy and Infectious Diseases Research | 93.855 | La Jolla Institute for Immunology | 5U19AI142790 | 499,722 | - |
| Allergy and Infectious Diseases Research | 93.855 | Los Angeles Biomedical Research Institute | 5U01AI11640005 | 67,007 | - |
| Allergy and Infectious Diseases Research | 93.855 | Massachusetts General Hospital | 1U01AI16308601 | 28 | - |
| Allergy and Infectious Diseases Research | 93.855 | Massachusetts General Hospital | 5U01AI16308602 | 150,066 | - |
| Allergy and Infectious Diseases Research | 93.855 | Massachusetts General Hospital | 5U01AI16308603 | 9,469 | - |
| Allergy and Infectious Diseases Research | 93.855 | Massachusetts General Hospital | 5U01AI16308603 - 239761 | 28,981 | - |
| Allergy and Infectious Diseases Research | 93.855 | Michigan State University | 5U01AI12661006 | 8,589 | - |
| Allergy and Infectious Diseases Research | 93.855 | MicroBiotix Inc | 1R41AI16510201A1 | 62,610 | - |
| Allergy and Infectious Diseases Research | 93.855 | National Children's Research Centre | 5U01AI155300-03 | 33,295 | - |
| Allergy and Infectious Diseases Research | 93.855 | Northwestern University | 5P30AI11794310 | 55,416 | - |
| Allergy and Infectious Diseases Research | 93.855 | Oregon Health & Science University | 5R01AI13218605 | 581 | - |
| Allergy and Infectious Diseases Research | 93.855 | Regents Of The University Of Colorado | 5R01AII4143605 | 179,794 | - |
| Allergy and Infectious Diseases Research | 93.855 | Regents Of The University Of Michigan | 2R01AI11262606A1 | 237,397 | - |
| Allergy and Infectious Diseases Research | 93.855 | Regents Of The University Of Michigan | 2R01AI13467805 | 232,583 | - |
| Allergy and Infectious Diseases Research | 93.855 | Regents Of The University Of Michigan | 5U54AI17066002 | 194,065 | - |
| Allergy and Infectious Diseases Research | 93.855 | Saint Louis University | 1R01AI13019001A1 | (47) | - |
| Allergy and Infectious Diseases Research | 93.855 | Saint Louis University | 5R01AI13019002 | 68,970 | - |
| Allergy and Infectious Diseases Research | 93.855 | Scripps Research Institute | 1U19AI17144301 | 244,500 | - |
| Allergy and Infectious Diseases Research | 93.855 | Scripps Research Institute | 5U19AI17144302 | 165,301 | - |
| Allergy and Infectious Diseases Research | 93.855 | St. Jude Children's Research Hospital | 5U01AI144616 | 169,268 | - |
| Allergy and Infectious Diseases Research | 93.855 | Temple University | 1UM1AI164568-02 | 494,049 | - |
| Allergy and Infectious Diseases Research | 93.855 | Texas Tech University System | 1R15AI15674601A1 | 21,107 | - |
| Allergy and Infectious Diseases Research | 93.855 | The Board Of Trustees Of The Leland Stanford Junior University | 1R01AI178298-01A1 | 25,880 | - |
| Allergy and Infectious Diseases Research | 93.855 | The Board Of Trustees Of The Leland Stanford Junior University | 5U19AI16448408 | 149,791 | - |
| Allergy and Infectious Diseases Research | 93.855 | The Jackson Laboratory | 5U19AI14273305 | 109,639 | - |
| Allergy and Infectious Diseases Research | 93.855 | The Regents of the University of California | 1R01AI16989201A1 | 220,351 | - |
| Allergy and Infectious Diseases Research | 93.855 | The Regents of the University of California | 5R01AI11463508 | 15,052 | - |
| Allergy and Infectious Diseases Research | 93.855 | The Regents of the University of California | 7R21AI15204902 | 15,892 | - |
| Allergy and Infectious Diseases Research | 93.855 | Thomas Jefferson University | 5R01AI16584002 | 42,648 | - |
| Allergy and Infectious Diseases Research | 93.855 | Trustees Of The University Of Pennsylvania | 1R01AI18004701 | 86,108 | - |
| Allergy and Infectious Diseases Research | 93.855 | Trustees Of The University Of Pennsylvania | 1R01AI18100701 | 59,111 | - |
| Allergy and Infectious Diseases Research | 93.855 | Trustees Of The University Of Pennsylvania | 5R01AI14053905 | 99,220 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Alabama Birmingham | 5U19AI14275905 | 119,684 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Alabama Birmingham | 5U54AI15022503 | 5,209 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Alabama Birmingham | 5U54AI15022504 | 9,856 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Arizona | 2R01AI12994506 | 122,411 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of Calgary | 5R01AI16532702 | 99,942 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of California Los Angeles | 2UM1AI06863615 | 351,461 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of California Los Angeles | 5UM1AI06863616 | 59,050 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of California, San Francisco | 1P01AI15539301A1 | 325,418 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of California, San Francisco | 5P01AI155393-03 | 184,994 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of California, Santa Barbara | 5R21AI16448302 | 160,188 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Florida | 5R01AI14147805 | 5,084 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of Georgia Research Foundation | 1R01AI173416-01A1 | 20,794 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of Georgia Research Foundation | R21AI178556 | 27,346 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Kentucky | 5R01AI14075805 | 107,143 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Louisville | 1R01AI3967101A1 | 1,129 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Pittsburgh | 1R01AI165519-01A1 | 18,101 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Pittsburgh | 1R01AI178378-01 | 60,173 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Pittsburgh | 1R21AI163606-02 | 17 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Pittsburgh | 1R56AI17192001 | 208,887 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Pittsburgh | 5R01AI14266205 | 9,582 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Allergy and Infectious Diseases Research | 93.855 | University of Pittsburgh School of Medicine | 5R01AI15021403 | 123,779 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of Texas Medical Branch | 5R01AI14635302 | 226,432 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of Texas Southwestern | 5U19AI142784 | 738,006 | - |
| Allergy and Infectious Diseases Research | 93.855 | University of Washington | 5R01AI14529605 | 209,006 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Wisconsin | 1R01AI15067801 | 349,614 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Wisconsin | 1UM1AI16004001 | 221,768 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Wisconsin | 1UM1AI16004002 | 382,567 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Wisconsin | 5P01AI13213205 | 20,033 | - |
| Allergy and Infectious Diseases Research | 93.855 | University Of Wisconsin | 5R01AI15313004 | 126,191 | - |
| Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University | 5UM1AI14845204 | 20,421 | - |
| Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University | 5UM1AI14845205 | 34,148 | - |
| Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University Medical Center | 1R01AI17215601 | 399,512 | - |
| Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University Medical Center | 3UM1AI14845203S3 | 989,578 | - |
| Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University Medical Center | 5UM1AI06861912 | 11,975 | - |
| Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University Medical Center | 5UM1AI069439 | 696,610 | - |
| COVID-Allergy and Infectious Diseases Research | 93.855 | Vanderbilt University Medical Center | UM1AI068619 | (6,834) | - |
| Allergy and Infectious Diseases Research | 93.855 | VaxNewMo, LLC | 1R41AI16707801 | 97,660 | - |
| Allergy and Infectious Diseases Research | 93.855 | VaxNewMo, LLC | 1R42AI165116 | 153,466 | - |
| Allergy and Infectious Diseases Research | 93.855 | Washington State University | 5U01AI5179905 | 180,939 | - |
| Allergy and Infectious Diseases Research | 93.855 | Weill Medical College of Cornell University | 5U01AI095608-13 | 481,689 | - |
| Biomedical Research and Research Training | 93.859 | | | 38,394,730 | 515,405 |
| Biomedical Research and Research Training | 93.859 | Cornell University | 1R25GM14207001 | 88,519 | - |
| Biomedical Research and Research Training | 93.859 | Florida International University | 5R01GM13424703 | 20,822 | - |
| Biomedical Research and Research Training | 93.859 | Icahn School Of Medicine At Mount Sinai | 7R01GM14344002 | 62,196 | - |
| Biomedical Research and Research Training | 93.859 | Northeastern University | R01GM121612 | 24,505 | - |
| Biomedical Research and Research Training | 93.859 | Protein Metrics Inc | 2R42GM12113302 | (316) | - |
| Biomedical Research and Research Training | 93.859 | Saint Louis University | 1R01GM134081 | 70,192 | - |
| Biomedical Research and Research Training | 93.859 | University Of Alabama Birmingham | 5R25GM13051704 | 131,171 | - |
| Biomedical Research and Research Training | 93.859 | University Of Florida | 5R01GM13904603 | 204,820 | - |
| Biomedical Research and Research Training | 93.859 | University Of Texas | 5R01GM11423708 | 84,516 | - |
| Biomedical Research and Research Training | 93.859 | Vanderbilt University | 5R01GM11661607 | 3,901 | - |
| Child Health and Human Development Extramural Research | 93.865 | | | 21,164,201 | 4,818,581 |
| Child Health and Human Development Extramural Research | 93.865 | Boston University | 5R01HD07281509 | 29,695 | - |
| Child Health and Human Development Extramural Research | 93.865 | Boston University | 5R01HD09113005 | 45,120 | - |
| Child Health and Human Development Extramural Research | 93.865 | Boston University | 5R01HD09244405 | 165,161 | - |
| Child Health and Human Development Extramural Research | 93.865 | Children's Hospital Of Philadelphia (The) | 1R01HD109963 | 287,488 | - |
| Child Health and Human Development Extramural Research | 93.865 | Johns Hopkins University | 5R01HD09769204 | 20,659 | - |
| Child Health and Human Development Extramural Research | 93.865 | Massachusetts General Hospital | R01HD113188-01 | 65,903 | - |
| Child Health and Human Development Extramural Research | 93.865 | Medical College Of Wisconsin | 5R01HD10460702 | 13,685 | - |
| Child Health and Human Development Extramural Research | 93.865 | Nationwide Children's Hospital | 5R01HD09134704 | 1,366 | - |
| Child Health and Human Development Extramural Research | 93.865 | Neurolutions | 4R44HD105579-02 | 173,317 | - |
| Child Health and Human Development Extramural Research | 93.865 | Northwestern University | 5K12HD07394510 | (304) | - |
| Child Health and Human Development Extramural Research | 93.865 | Oregon Health & Science University | U24HD100982 | 3,099 | - |
| Child Health and Human Development Extramural Research | 93.865 | Oregon Health & Science University | U54HD100982 | 219,337 | - |
| Child Health and Human Development Extramural Research | 93.865 | Rector & Visitors Of The University Of Virginia | 1R01HD110568-01A1 | 34,083 | - |
| Child Health and Human Development Extramural Research | 93.865 | Rector & Visitors Of The University Of Virginia | 5R01HD072071 | 162,668 | - |
| Child Health and Human Development Extramural Research | 93.865 | Regents Of The University Of Colorado | 5R01HD09799004 | 68,102 | - |
| Child Health and Human Development Extramural Research | 93.865 | Regents Of The University Of Michigan | 1R01HD109251-01A1 | 107,039 | - |
| Child Health and Human Development Extramural Research | 93.865 | Seattle Children's Hospital, Research and Foundation | 5R01HD102239-03 | 39,056 | - |
| Child Health and Human Development Extramural Research | 93.865 | St. Louis College of Pharmacy | 3R33HD09974805S1 | 53,053 | - |
| Child Health and Human Development Extramural Research | 93.865 | Children's Hospital Of Philadelphia (The) | 5R01HD10152804 | 46,215 | - |
| Child Health and Human Development Extramural Research | 93.865 | Trustees Of Columbia University In the City Of New York | 1R01HD112241-01A1 | 7,107 | - |
| Child Health and Human Development Extramural Research | 93.865 | University at Buffalo | 5RO101HD10481402 | 9,504 | - |
| Child Health and Human Development Extramural Research | 93.865 | University Of Alabama Birmingham | 1R01HD11299401 | 17,216 | - |
| Child Health and Human Development Extramural Research | 93.865 | University of Massachusetts Medical School | 7R01HD09506005 | 11,485 | - |
| Child Health and Human Development Extramural Research | 93.865 | University Of North Carolina Chapel Hill | 2R01HD055741 | 420,612 | - |
| Child Health and Human Development Extramural Research | 93.865 | University Of North Carolina Chapel Hill | 5R01HD10390203 | 27,929 | - |
| Child Health and Human Development Extramural Research | 93.865 | University of Pittsburgh School of Medicine | 1R25HD109110-01 | 9,418 | - |
| Child Health and Human Development Extramural Research | 93.865 | University of Texas Southwestern | 5P01HD08438707 | 495,792 | 220,802 |
| Child Health and Human Development Extramural Research | 93.865 | University of Washington | 5R01HD10157802 | 114,853 | - |
| Child Health and Human Development Extramural Research | 93.865 | Virginia Polytechnic Institute And State University | 5P2CHD10191204 | 18,986 | - |
| Child Health and Human Development Extramural Research | 93.865 | Women and Infants Hospital of Rhode Island | 1R01HD10821001 | 54,075 | - |
| Child Health and Human Development Extramural Research | 93.865 | Women and Infants Hospital of Rhode Island | 5R01HD10585502 | 97,592 | - |
| Child Health and Human Development Extramural Research | 93.865 | Yale University | 5R01HD106326-02 | 3,577 | - |
| Aging Research | 93.866 | | | 109,365,749 | 22,509,857 |
| COVID-Aging Research | 93.866 | | | 1,622,812 | 555,311 |
| Aging Research | 93.866 | Active Life Scientific | R44AG071034 | 116,222 | - |
| Aging Research | 93.866 | Baylor College of Medicine | 5P01AG06660603 | 345,853 | - |
| Aging Research | 93.866 | Baylor University | 5R01AG06529002 | 67,997 | - |
| Aging Research | 93.866 | customized learning Exercises for Aural Rehabilitation, LLC | 1R43AG06507501A1 | (452) | - |
| Aging Research | 93.866 | Duke University | 1U19AG06518801 | 100,833 | - |
| Aging Research | 93.866 | George Washington University | 1U19AG078558-01 | 310,664 | - |
| Aging Research | 93.866 | Harvard School of Public Health | 5R01AG06093503 | 99,194 | - |
| Aging Research | 93.866 | Hebrew Rehabilitation Center | 5R33AG07174402 | 14,187 | - |
| Aging Research | 93.866 | Indiana University | 5U01AG05719504 | 1,418 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Aging Research | 93.866 | Indiana University | 5U01AG05719505 | 253,505 | - |
| Aging Research | 93.866 | Johns Hopkins University | 1RF1AG05986901 | 449,687 | - |
| Aging Research | 93.866 | Johns Hopkins University | 5R01AG04028209 | 3,428 | - |
| Aging Research | 93.866 | Mayo Clinic | 1U19AG06970101 | 264,458 | - |
| Aging Research | 93.866 | Mayo Clinic | 1U19AG07487901A1 | 102,684 | - |
| Aging Research | 93.866 | Mayo Clinic | 3U19AG06391102S1 | 365,715 | - |
| Aging Research | 93.866 | Mayo Clinic | 5K23AG06402904 | 5,697 | - |
| Aging Research | 93.866 | Mayo Clinic | 5R01AG075802-03 | 23,703 | - |
| Aging Research | 93.866 | Mayo Clinic | 5U19AG06391103 | 183,398 | - |
| Aging Research | 93.866 | Mayo Clinic | 5U19AG06970102 | 674,407 | - |
| Aging Research | 93.866 | Mayo Clinic | 5U19AG06970103 | 477,201 | - |
| Aging Research | 93.866 | Mayo Clinic | WUB-284424/PO #69081362 | 79,739 | - |
| Aging Research | 93.866 | Medical College Of Wisconsin | 1R01AG07773201 | 431,296 | - |
| Aging Research | 93.866 | Northern California Institute For Research And Education | 2U19AG02490416 | 629,578 | - |
| Aging Research | 93.866 | Northwestern University | 5U2CAG060260404S1 | (12,227) | - |
| Aging Research | 93.866 | Ohio State University | R01AG056919A | (3,347) | - |
| Aging Research | 93.866 | Parabon Nanolabs Inc | 2R44AG06207202A1 | 76,170 | - |
| Aging Research | 93.866 | Pelagos Pharmaceuticals Inc | 1R41AG07977801A1 | 121,219 | - |
| Aging Research | 93.866 | Pennsylvania State University | 5U2CAG06040805 | 32,787 | - |
| Aging Research | 93.866 | Rector & Visitors Of The University Of Virginia | 5R01AG06704802 | 103,654 | - |
| Aging Research | 93.866 | Regenerative Research Foundation | 1U1AG072464 | 506,199 | - |
| Aging Research | 93.866 | Regents Of The University Of California | 1RF1AG05900901 | 129,083 | - |
| Aging Research | 93.866 | Regents Of The University Of Michigan | 1R01AG07401201 | 99,614 | 1,372 |
| Aging Research | 93.866 | Regents Of The University Of Michigan | 5U24AG06518204 | 34,690 | - |
| Aging Research | 93.866 | Rutgers The State University Of NJ | 7R01AG076774-02 | 7,580 | - |
| Aging Research | 93.866 | The Brigham And Women's Hospital Inc | 5RF1AG07956902 | 58,354 | - |
| Aging Research | 93.866 | The Jackson Laboratory | 5R01AG07401202 | 3,639 | 1,216 |
| Aging Research | 93.866 | The Regents of the University of California | 5R01AG06114604 | 11,510 | - |
| Aging Research | 93.866 | Trustees Of Columbia University In the City Of New York | 5U24UA05627007 | 100,086 | - |
| Aging Research | 93.866 | Trustees Of Columbia University In the City Of New York | 5U24UA5627004 | (1,988) | - |
| Aging Research | 93.866 | Trustees Of The University Of Pennsylvania | 1R01AG06857701 | 23,268 | - |
| Aging Research | 93.866 | Trustees Of The University Of Pennsylvania | 1R01AG06993601A1 | 100,725 | - |
| Aging Research | 93.866 | Trustees Of The University Of Pennsylvania | 5P01AG03186215 | 2,790 | - |
| Aging Research | 93.866 | Trustees Of The University Of Pennsylvania | 5R01AG05443503 | (718) | - |
| Aging Research | 93.866 | Trustees Of The University Of Pennsylvania | 7RF1AG06719402 | 48,337 | - |
| Aging Research | 93.866 | Tufts University | 5R01AG07171702 | 265,185 | - |
| Aging Research | 93.866 | University Of Alabama Birmingham | 1R01AG06839501A1 | (1,232) | - |
| Aging Research | 93.866 | University Of Alabama Birmingham | 1R01AG081228-01 | 53,001 | - |
| Aging Research | 93.866 | University Of Alabama Birmingham | 5R01AG06839503 | 25,105 | - |
| Aging Research | 93.866 | University Of California Berkeley | 1R01AG07895801 | 213,306 | - |
| Aging Research | 93.866 | University of California, San Francisco | 1R01AG080469-01 | 21,443 | - |
| Aging Research | 93.866 | University of California, San Francisco | 1R01AG078457-01A1 | 6,443 | - |
| Aging Research | 93.866 | University of California, San Francisco | 5P30AG06242205 | 20,011 | - |
| Aging Research | 93.866 | University of California, San Francisco | 5R01AG06235905 | 22,228 | - |
| Aging Research | 93.866 | University Of Florida | 1RF1AG077160-01A1 | 145,036 | - |
| Aging Research | 93.866 | University Of Florida | 7RF1AG060769-07 | 54,113 | - |
| Aging Research | 93.866 | University Of Florida | R37AG033906 | 48,208 | - |
| Aging Research | 93.866 | University of Illinois Chicago | 5R01AG07654102 | 143,361 | - |
| Aging Research | 93.866 | University Of Kentucky | 5R01AG03865109 | 16,797 | - |
| Aging Research | 93.866 | University of Melbourne | 5R01AG05867604 | 510,778 | - |
| Aging Research | 93.866 | University Of Miami | 5R01AG06461404 | 112,620 | - |
| Aging Research | 93.866 | University Of North Texas Health Science Center | 1U19AG078109-01 | 59,444 | - |
| Aging Research | 93.866 | University Of North Texas Health Science Center | 5U19AG078109-02 | 302,543 | - |
| Aging Research | 93.866 | University Of Pittsburgh | 1R01AG06487701A1 | 909,926 | - |
| Aging Research | 93.866 | University Of Pittsburgh | 1U19AG06805401 | (1,380) | - |
| Aging Research | 93.866 | University Of Pittsburgh | 5R01AG06049905 | 44,986 | - |
| Aging Research | 93.866 | University Of Pittsburgh | 5U19AG06805403 | 710,651 | - |
| Aging Research | 93.866 | University Of Pittsburgh | 5U19AG06805403S1 | 4,135 | - |
| Aging Research | 93.866 | University Of Pittsburgh | 5U19AG06805404 | 321,023 | - |
| Aging Research | 93.866 | University of Pittsburgh School of Medicine | 1R01AG07326701 | 915,231 | - |
| Aging Research | 93.866 | University of Rhode Island | 1R01AG079241-01 | 463,606 | - |
| Aging Research | 93.866 | University of Rhode Island | 5R01AG07924102 | 178,314 | - |
| Aging Research | 93.866 | University Of Rochester | 5P01AG04720009 | 63,866 | - |
| Aging Research | 93.866 | University Of Southern California | 1R01AG05379801A1 | 42,001 | - |
| Aging Research | 93.866 | University Of Southern California | 1R01AG06184801 | 6,617 | - |
| Aging Research | 93.866 | University Of Southern California | 1R01AG06368901 | 199,674 | - |
| Aging Research | 93.866 | University Of Southern California | 1R61AG06654301 | 44,121 | - |
| Aging Research | 93.866 | University Of Southern California | 2P01AG05235006 | 117,938 | - |
| Aging Research | 93.866 | University Of Southern California | 5P01AG05235005 | (1,530) | - |
| Aging Research | 93.866 | University Of Southern California | 5P01AG05235007 | 293,199 | - |
| Aging Research | 93.866 | University Of Southern California | 5R01AG05379803 | 26,373 | - |
| Aging Research | 93.866 | University Of Southern California | 5R01AG05379804 | 2,784 | - |
| Aging Research | 93.866 | University Of Southern California | 5R01AG05379805 | 1,742 | - |
| Aging Research | 93.866 | University Of Southern California | 5R01AG05402902 | 41,245 | - |
| Aging Research | 93.866 | University Of Southern California | 5R21AG08041402 | 19,838 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Aging Research | 93.866 | University Of Southern California | 5R61AG06654302 | 10,545 | - |
| Aging Research | 93.866 | University Of Southern California | 5U19AG02490417 | 60,028 | - |
| Aging Research | 93.866 | University Of Southern California | 5U24AG05743704 | 134,963 | - |
| Aging Research | 93.866 | University Of Texas Health Science Center At San Antonio | 5R01AG05789604 | 15,402 | - |
| Aging Research | 93.866 | University of Washington | 1U24AG07212201 | (23) | - |
| Aging Research | 93.866 | University of Washington | 3U24AG07212201S1 | 92,607 | - |
| Aging Research | 93.866 | University of Washington | 5R01AG06375902 | 14,675 | - |
| Aging Research | 93.866 | University of Washington | 5U24AG07212202 | 20,776 | - |
| Aging Research | 93.866 | University Of Wisconsin | 5R01AG07002802 | 268,017 | - |
| Aging Research | 93.866 | University Of Wisconsin | 5R01AG07088302 | 40,153 | - |
| Aging Research | 93.866 | Van Andel Research Institute | 1R01AG08356801 | 37,819 | - |
| Aging Research | 93.866 | Vanderbilt University Medical Center | 1R01AG07343901 | 248,960 | - |
| Aging Research | 93.866 | Vanderbilt University Medical Center | 5U24AG07485502 | 541,396 | - |
| Aging Research | 93.866 | Vivid Genomics Inc | 1R43AG07610601A1 | 311 | - |
| Aging Research | 93.866 | Wake Forest University | 1R01AG078153-01 | 11,862 | - |
| Aging Research | 93.866 | Wake Forest University | 5R01AG078153-02 | 124,264 | - |
| Aging Research | 93.866 | WNT Scientific LLC | 1R41AG080953-01A1 | 146,005 | - |
| Aging Research | 93.866 | Yale University | 5R01AG06591703 | 236,113 | - |
| Aging Research | 93.866 | Yale University | 5R01AG073969-02 | 182,956 | - |
| Vision Research | 93.867 | | | 9,117,483 | 699,974 |
| Vision Research | 93.867 | Banner Alzheimer's Institute | 1RF1AG073424 | 12,157 | - |
| Vision Research | 93.867 | Children's Hospital Corporation | 1R01EY035684-01 | 114,934 | - |
| Vision Research | 93.867 | Jaeb Center for Health Research Foundation Inc | U10EY11751 | 4,306 | - |
| Vision Research | 93.867 | Johns Hopkins University | 5UG1EY02809103 | 45,662 | - |
| Vision Research | 93.867 | Legacy Emanuel Hospital & Health Center | R01EY034554 | 29,012 | - |
| Vision Research | 93.867 | University Of California Irvine | 1R01EY03513701 | 163,035 | - |
| Vision Research | 93.867 | University Of Iowa | 1R01EY035266-01 | 27,566 | - |
| Vision Research | 93.867 | University of Massachusetts Medical School | 5R01EY02860203 | 30 | - |
| Vision Research | 93.867 | University of Missouri System | 1R21EY02910601A1 | (14,937) | - |
| Vision Research | 93.867 | University of Missouri System | 2R01EY027824-06 | 53,067 | - |
| Vision Research | 93.867 | West Virginia University | 5UG1EY03165403 | 20,822 | - |
| Medical Library Assistance | 93.879 | | | 440,101 | 89,631 |
| Medical Library Assistance | 93.879 | University of California, San Francisco | 5R01LM01377804 | 110,278 | - |
| Global Health Research and Research Training | 93.989 | | | 1,784,243 | 798,450 |
| Global Health Research and Research Training | 93.989 | Centre for Infectious Disease Research in Zambia | 1D71TW01183702 | 3,290 | - |
| Global Health Research and Research Training | 93.989 | Northwestern University | 5D43TW01197603 | 5,681 | - |
| Global Health Research and Research Training | 93.989 | University Of North Carolina Chapel Hill | 2D43TW009340-11 | 22,564 | - |
| National Center for Advancing Translational Sciences (NCATS) | 93.RD | Harvard University | 75N95023C00008 | 36,826 | - |
| COVID-National Center for Advancing Translational Sciences (NCATS) | 93.RD | Regenstrief Institute | 75N95021D00028 | 287,197 | - |
| National Cancer Institute (NCI) | 93.RD | ICF Incorporated, LLC | GS-OOF-01OCA/ HHSN261201700003B/ 75N91022F00002/TO9 | 145,497 | - |
| National Cancer Institute (NCI) | 93.RD | Leidos Biomedical Research | 75N91019D00024 | 46,205 | - |
| COVID-National Cancer Institute (NCI) | 93.RD | Leidos Biomedical Research | 75N91019D00024 | 354,114 | - |
| National Cancer Institute (NCI) | 93.RD | Leidos Biomedical Research | 75N91020F00030 | 1,254 | - |
| National Cancer Institute (NCI) | 93.RD | Leidos Biomedical Research | 75N9120F00003 | 315,967 | - |
| National Cancer Institute (NCI) | 93.RD | Leidos Biomedical Research | HHSN261201500003I | 78,901 | - |
| National Cancer Institute (NCI) | 93.RD | Medical Science & Computing | 75N98020D00086/75N98020F0 | 4,002 | - |
| National Cancer Institute (NCI) | 93.RD | Medical Science & Computing | 75N98020F00014 | 755 | - |
| National Cancer Institute (NCI) | 93.RD | Oregon Health & Science University | HHSN26120622012C | 13,804 | - |
| National Cancer Institute (NCI) | 93.RD | TetraImaging, LLC | 75N91022C00055 | 29,387 | - |
| COVID-National Cancer Institute (NCI) | 93.RD | Westat | 1OT2HL16161401 | 1,140,995 | 45,673 |
| COVID-National Cancer Institute (NCI) | 93.RD | Westat | 5OT2HL16161402 | 1,187,479 | - |
| National Heart, Lung and Blood Institute (NHLBI) | 93.RD | | | 47,163 | - |
| National Heart, Lung and Blood Institute (NHLBI) | 93.RD | Duke University | 1OT2HL156812-01 | 37,373 | - |
| National Heart, Lung and Blood Institute (NHLBI) | 93.RD | Emmes Company | HHSN268201400002I | 57,259 | - |
| COVID-National Heart, Lung and Blood Institute (NHLBI) | 93.RD | L3 Healthcare | 75N92021D00008 | 2,306 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | | | 2,251,083 | 451,315 |
| COVID-National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Fred Hutchinson Cancer Center | 0001118806 | 63,499 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Ichan School of Medicine at Mt. Sinai | 75N93021C00014 | 1,684,600 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Ichan School of Medicine at Mt. Sinai | 75N93019C00051 | 569,871 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Institute for Clinical Research | 75N91019D00024 | 1,632 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Northwestern University | 75N93021R00009 | 28,528 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Northwestern University | 75N93022C00035 | 457,098 | - |
| COVID-National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Northwestern University | 75N93022C00035 | 57,895 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Northwestern University | HHSN272201700060C | (305) | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | Seattle Children's Research Institute | 75N93022C00036 | 49,156 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | St. Jude Children's Research Institute | 75N93021C00016 | 649,695 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | University Of Alabama Birmingham | HHSN272201600017C | 5,463 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | University Of Alabama Birmingham | HHSN272201600018C | 43,050 | - |
| National Institute of Allergy and Infectious Diseases (NIAID) | 93.RD | University Of Maryland College Park | 75N93023C0046 | 46,108 | - |
| National Institute on Drug Abuse (NIDA) | 93.RD | Rutgers University | 75N95023D0009 | 364,396 | - |
| National Institutes of Health (NIH) | 93.RD | Duke University | HHSN275201000003I | 4,194 | - |
| National Institutes of Health (NIH) | 93.RD | RTI International | OT3 HL147798-01 | 87,584 | - |
| National Institutes of Health (NIH) | 93.RD | Vivent | RWB_VIVENTTOWU_FY20-21 | 139,347 | - |
| National Institutes of Health (NIH) | 93.RD | Westat | HHSN261201600007I | 14,760 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| **Office of the Assistant Secretary for Planning and Evaluation** | | | | | |
| Policy Research and Evaluation Grants | 93.239 | University Of Wisconsin | 1H79AE000058-02 | 776 | - |
| **Office on Women's Health** | | | | | |
| COVID-Advancing System Improvements for Key Issues in Women's Health | 93.088 | | | 430,671 | - |
| **Substance Abuse and Mental Health Services Administration** | | | | | |
| Projects of Regional and National Significance | 93.243 | | | 42,537 | - |
| Projects of Regional and National Significance | 93.243 | University of Missouri, St. Louis | SM085050 | 16,264 | - |
| TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES | | | | 763,709,268 | 93,980,877 |
| | | | | | |
| **NATIONAL AERONAUTICS AND SPACE ADMINSTRATION** | | | | | |
| **National Aeronautics and Space Administration** | | | | | |
| Science | 43.001 | | | 11,401,539 | 2,076,696 |
| Science | 43.001 | Colorado School of Mines | 80NSSC22K1105 | 39,504 | - |
| Science | 43.001 | Johns Hopkins University | 80NSSC24M0004 | 24,106 | - |
| Science | 43.001 | Rensselaer Polytechnic Institute | 80NSSC19M0069 | 81,510 | - |
| Science | 43.001 | Smithsonian Institution | G0324018B | 9,969 | - |
| Science | 43.001 | Smithsonian Institution | G03-24078B | 28,158 | - |
| Science | 43.001 | Smithsonian Institution | GO122033B | (8,982) | - |
| Science | 43.001 | Smithsonian Institution | NAS8-03060 | 6,719 | - |
| Science | 43.001 | University of Chicago | 80NSSC21M0116 | 238,375 | - |
| Science | 43.001 | University of Georgia | 80NSSC22K0132 | 16,003 | - |
| Science | 43.001 | University of New Mexico | 80NSSC19K0958 | 85,688 | - |
| Science | 43.001 | | | 3,359 | - |
| Space Operations | 43.007 | | | 21,387 | - |
| Education | 43.008 | University of Missouri System | 80NSSC20M0100 | 64,708 | - |
| Space Technology | 43.012 | | | 739,248 | 375,046 |
| NASA | 43.RD | Arizona State University | NNG07EK00C | 134,494 | - |
| NASA | 43.RD | Jet Propulsion Laboratory | 1658021 | (157) | - |
| NASA | 43.RD | Jet Propulsion Laboratory | NM0710630 | 20,870 | - |
| NASA | 43.RD | Jet Propulsion Laboratory | NMO710805 | 36,116 | - |
| NASA | 43.RD | Johns Hopkins University | 80MSFC20D0004 | 110,851 | - |
| NASA | 43.RD | Southwest Research Institute | NASW-02008 | 28,624 | - |
| NASA | 43.RD | Southwest Research Institute | NNN12AA01C | 58,992 | - |
| NASA | 43.RD | University of Texas Austin | NNM16AA26C | 4,189 | - |
| TOTAL NATIONAL AERONAUTICS AND SPACE ADMINSTRATION | | | | 13,145,270 | 2,451,742 |
| | | | | | |
| **NATIONAL SCIENCE FOUNDATION** | | | | | |
| **National Science Foundation** | | | | | |
| National Science Foundation | 47.RD | | | 318,512 | - |
| Engineering Grants | 47.041 | | | 3,087,385 | 250,396 |
| Engineering Grants | 47.041 | OsciFlex LLC | 2132561 | 32,176 | - |
| Engineering Grants | 47.041 | Renerva LLC | 2151582 | 86,567 | - |
| Engineering Grants | 47.041 | Trustees Of The University Of Pennsylvania | CMMI-1548571 | 1,038,213 | - |
| Engineering Grants | 47.041 | University of Central Florida | 1908167 | (680) | - |
| Engineering Grants | 47.041 | University of Illinois at Urbana-Champaign | 1900277 | 68,989 | - |
| Engineering Grants | 47.041 | University of Pittsburgh | CBET-2326096 | 8,504 | - |
| Mathematic and Physical Sciences | 47.049 | | | 4,770,098 | 120,535 |
| Mathematic and Physical Sciences | 47.049 | Barnard College | 1828168 | (1,809) | - |
| Mathematic and Physical Sciences | 47.049 | Harvard University | 2127882 | 310,618 | - |
| Mathematic and Physical Sciences | 47.049 | Missouri University of Science and Technology | CHE-2155175 | 24,498 | - |
| Mathematic and Physical Sciences | 47.049 | Smithsonian Institution | SV121007 | 7,000 | - |
| Mathematic and Physical Sciences | 47.049 | Southern Illinois University Edwardsville | 2328837 | 27,245 | - |
| Mathematic and Physical Sciences | 47.049 | University of Nevada at Reno | 2326801 | 50,494 | - |
| Geosciences | 47.050 | | | 1,018,490 | - |
| Computer and Information Science and Engineering | 47.070 | | | 4,182,584 | 97,752 |
| Computer and Information Science and Engineering | 47.070 | Colorado School of Mines | 2118201 | 93,964 | - |
| Computer and Information Science and Engineering | 47.070 | University Of California Berkeley | 1640899 | (2,719) | - |
| Computer and Information Science and Engineering | 47.070 | University of Illinois at Urbana-Champaign | 2103680 | 25,241 | - |
| Computer and Information Science and Engineering | 47.070 | University of Utah | 2002158 | 269,929 | - |
| Computer and Information Science and Engineering | 47.070 | University of Utah | CNS182688 | 51,019 | - |
| Computer and Information Science and Engineering | 47.070 | University of Utah | CNS1827940 | 47,330 | - |
| Computer and Information Science and Engineering | 47.070 | West Virginia University | IIS-2114644 | (380) | - |
| Biological Sciences | 47.074 | | | 5,058,832 | 515,055 |
| Biological Sciences | 47.074 | American University | 1948181 | 35,252 | - |
| Biological Sciences | 47.074 | Baylor College of Medicine | 2131806 | 62,868 | - |
| Biological Sciences | 47.074 | Baylor College of Medicine | DBI-2021795 | 223,306 | - |
| Biological Sciences | 47.074 | Carnegie Institution of Washington | DBI-2213983 | 917 | - |
| Biological Sciences | 47.074 | Michigan State University | 2243230 | 63,709 | - |
| Biological Sciences | 47.074 | Michigan State University | 2419923 | 68,369 | - |
| Biological Sciences | 47.074 | University of Wisconsin, Madison | 1840687 | 73,335 | - |
| Social, Behavioral, and Economic Sciences | 47.075 | | | 1,208,835 | - |
| Social, Behavioral, and Economic Sciences | 47.075 | Boston University | SES2120115 | 21,179 | - |
| Social, Behavioral, and Economic Sciences | 47.075 | Rice University | 2243593 | 24,179 | - |
| Education and Human Resources | 47.076 | | | 2,010,762 | - |
| Education and Human Resources | 47.076 | Baylor University | 1920730 | 80,872 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Education and Human Resources | 47.076 | Jackson State University | 2000135 | 1,088 | - |
| Education and Human Resources | 47.076 | University of Alabama | 1915544 | 55,295 | - |
| Polar Programs | 47.078 | | | 73,303 | - |
| Office of International Science and Engineering | 47.079 | | | 90,008 | 29,497 |
| Office of International Science and Engineering | 47.079 | CFDF Global | 202304-70821 | 20,999 | - |
| Office of International Science and Engineering | 47.079 | University of Wisconsin | OISE-20-66590-1 | 3,075 | - |
| Office of Integrative Activities | 47.083 | | | 895,270 | - |
| NSF Technology, Innovation, and Partnerships | 47.084 | | | 768,892 | 99,200 |
| NSF Technology, Innovation, and Partnerships | 47.084 | Massachusetts Institute Of Technology | TI-2229704 | 3,539 | - |
| TOTAL NATIONAL SCIENCE FOUNDATION | | | | 26,357,152 | 1,112,435 |
| | | | | | |
| **AGENCY FOR INTERNATIONAL DEVELOPMENT** | | | | | |
| **Agency for International Development** | | | | | |
| Agency for International Development Foreign Assistance for Programs Overseas | 98.001 | Mississippi State University | 7200AA18CA00030 | 47,479 | - |
| Agency for International Development Foreign Assistance for Programs Overseas | 98.001 | National Academy of Sciences | AID263A1500002 | (10,136) | - |
| Agency for International Development Foreign Assistance for Programs Overseas | 98.001 | University Of Georgia | 7200AA18CA00003 | 168,045 | 25,000 |
| Agency for International Development | 98.RD | Mississippi State University | 19390031245502E | 16,156 | - |
| Agency for International Development | 98.RD | Mississippi State University | 7200AA18CA00030 | 345 | - |
| Agency for International Development | 98.RD | Tufts University | 7200AA18CA00030 | 100,494 | 43,734 |
| **DEPARTMENT OF AGRICULTURE** | | | | | |
| **National Institute of Food and Agriculture** | | | | | |
| Biotechnology Risk Assessment Research | 10.219 | | | 251,614 | - |
| Agriculture and Food Research Initiative (AFRI) | 10.310 | | | 55,234 | 41,986 |
| Agriculture and Food Research Initiative (AFRI) | 10.310 | Washington State University | 2022-68016-37113 | 80,871 | - |
| **DEPARTMENT OF COMMERCE** | | | | | |
| Climate and Atmospheric Research | 11.431 | | | 49,250 | - |
| Weather and Air Quality Research | 11.459 | University of Wisconsin | NA23OAR4590411 | 8,218 | - |
| **DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT** | | | | | |
| **Department of Housing and Urban Development** | | | | | |
| Homeland Security Research, Development, Testing, Evaluation and Demonstration of Technologies Related to Countering Weapons of Mass Destruction | 97.077 | City of St. Louis | 19DNFRV000010201 | (1,159) | - |
| **DEPARTMENT OF JUSTICE** | | | | | |
| Crime Victim Assistance/Discretionary Grants | 16.582 | | | 105,072 | 54,716 |
| Public Safety Partnership and Community Policing Grants | 16.710 | Center for Naval Analyses | 15JCOPS21GK02399SPPS | 121,686 | - |
| Improving the Investigation and Prosecution of Child Abuse and the Regional and Local Children's Advocacy Centers | 16.758 | | | 34,364 | 924 |
| **DEPARTMENT OF STATE** | | | | | |
| International Programs to Combat Human Trafficking | 19.019 | | | 601,494 | 304,498 |
| Overseas Refugee Assistance Programs for Strategic Global Priorities | 19.522 | | | 1,734 | - |
| Bureau of Near Eastern Affairs | 19.600 | Johns Hopkins University | SMEAAC21CA3040 | 79,681 | - |
| **DEPARTMENT OF THE INTERIOR** | | | | | |
| Assistance to State Water Resources Research Institutes | 15.805 | University of Missouri System | G16AP00066 | (1,431) | - |
| **DEPARTMENT OF TRANSPORTATION** | | | | | |
| **Federal Highway Administration** | | | | | |
| National Highway Traffic Safety Administration | 20.RD | Wake Forest University | 693JJ922F00202N | 3,739 | - |
| National Highway Traffic Safety Administration | 20.RD | Wake Forest University | DTNH2217D00070 | (413) | - |
| **DEPARTMENT OF VETERANS AFFAIRS** | | | | | |
| Department of Veterans Affairs | 64.RD | | | 56,450 | - |
| Department of Veterans Affairs | 64.RD | University Of North Carolina Chapel Hill | 36C24120D0021 | 4,004 | - |
| **ENVIRONMENTAL PROTECTION AGENCY** | | | | | |
| Office of Research and Development | | | | | |
| Science to Achieve Results (STAR) Research Program | 66.509 | | | 160,586 | - |
| **UNITED STATES INSTITUTE OF PEACE** | | | | | |
| United States Institute of Peace | 91.RD | | | 42,704 | - |
| **Total Research & Development Cluster** | | | | 841,998,351 | 102,807,820 |
| | | | | | |
| **Other Sponsored Programs** | | | | | |
| **DEPARTMENT OF DEFENSE** | | | | | |
| **U.S. Army Medical Command** | | | | | |
| Military Medical Research and Development | 12.U01 | Synedgen Inc | (MTEC)-2021-476 | 53,230 | - |
| Military Medical Research and Development | 12.U02 | University of Pittsburgh School of Medicine | W81XWJ16D0024W81XWH18F04 | 35,074 | - |
| **TOTAL DEPARTMENT OF DEFENSE** | | | | 88,304 | - |
| | | | | | |
| **DEPARTMENT OF HEALTH AND HUMAN SERVICES** | | | | | |
| **Administration for Strategic Preparedness & Response** | | | | | |
| Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion | 93.078 | | | 29,738 | - |
| Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion | 93.078 | | | 3,526 | - |
| | | | | | |
| **Centers for Disease Control** | | | | | |
| Centers for Disease Control and Prevention | 93.U01 | | | 7,548 | - |
| Centers for Disease Control and Prevention | 93.U02 | | | 141,933 | - |
| Centers for Disease Control and Prevention | 93.U03 | | | 5,698 | - |
| Centers for Disease Control and Prevention | 93.U04 | | | 650,394 | - |
| | | | | | |
| Birth Defects and Developmental Disabilities - Prevention and Surveillance | 93.073 | Tourette Association of America, Inc. | NU38DD00001 | 34,568 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| Colorectal Cancer Screening Program | 93.800 | University of Missouri | 5NU58DP0067650300 | 18,363 | - |
| HIV Prevention Activities Non-Governmental Organization Based | 93.939 | Vivent Health | 1NU62PS924648-01-00 | 725 | - |
| HIV Prevention Activities Non-Governmental Organization Based | 93.939 | Vivent Health | 5NU62PS92464803-00 | 84,508 | - |
| HIV Prevention Activities_Health Department Based | 93.940 | Missouri Department of Health and Human Services | DH200047810 | 12,486 | - |
| HIV Prevention Activities_Health Department Based | 93.940 | City of St. Louis Department of Health | 11107110010 | 27,570 | - |
| HIV Prevention Activities_Health Department Based | 93.940 | City of St. Louis Department of Health | 11667114011 | 25,205 | - |
| HIV Prevention Activities_Health Department Based | 93.940 | City of St. Louis Department of Health | 6NU62PS92457705 | 31,729 | - |
| TOTAL HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED | | | | 96,990 | - |
| Preventive Health Services_Sexually Transmitted Diseases Control Grants | 93.977 | | | 215,455 | - |
| Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems | 93.988 | American Academy of Pediatrics | 1NU58DP007422-01-00 | 30,159 | - |
| Autism and Other Developmental Disabilities, Surveillance, Research, and Prevention | 93.998 | | | 527,759 | - |
| **Food and Drug Administration** | | | | | |
| Food and Drug Administration | 93.U05 | American College of Medical Toxicology Inc | 75F40122D00028 | 38,404 | - |
| Food and Drug Administration | 93.U06 | Children's Hospital Of Philadelphia (The) | 75F40120C00135 | 11,203 | - |
| **Health Resources and Services Administration** | | | | | |
| Health Resources and Services Administration | 93.U07 | Health Research Inc | HRSA15-0899-01 | 18,965 | - |
| Health Resources and Services Administration | 93.U08 | St Clair County | Unknown | 18,735 | - |
| Health Resources and Services Administration | 93.U09 | Vivent Health | CS232774001 | 55,749 | - |
| Emergency Medical Services for Children | 93.127 | Cincinnati Children's Hospital Medical Center | 2U03MC22684-13-00 | 135,950 | - |
| Emergency Medical Services for Children | 93.127 | Cincinnati Children's Hospital Medical Center | 5U03MC22684-11-00 | 51,744 | - |
| Emergency Medical Services for Children | 93.127 | University of Missouri System | 2H33MC31623-06-00 | 8,369 | - |
| TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN | | | | 196,063 | - |
| Sickle Cell Treatment Demonstration Program | 93.365 | | | 1,120,753 | 516,132 |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 21-84 | (987) | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 23-44 | 667,445 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 23-45 | 44,504 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 23-46 | 60,416 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 23-47 | 17,644 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 23-69 | 9,438 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 24-73 | 353,947 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 24-74 | 23,365 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 24-75 | 35,101 | - |
| HIV Emergency Relief Project Grants | 93.914 | City of St. Louis Department of Health | 24-76 | 10,421 | - |
| TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS | | | | 1,221,294 | - |
| HIV Care Formula Grants | 93.917 | Missouri Department of Health and Senior Services | 05780063H-4-1 | 81,116 | - |
| HIV Care Formula Grants | 93.917 | Missouri Department of Health and Senior Services | DH200048389 | 120,166 | - |
| HIV Care Formula Grants | 93.917 | Missouri Department of Health and Senior Services | DH230051646 | 501,235 | 105,100 |
| TOTAL HIV CARE FORMULA GRANTS | | | | 702,517 | 105,100 |
| Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease | 93.918 | | | 531,904 | 57,763 |
| Special Projects of National Significance | 93.928 | | | 52,702 | 38,692 |
| **Office of Assistant Secretary for Health** | | | | | |
| Family Planning Services | 93.217 | Missouri Family Health Council | FPHPA006561 | 229,390 | - |
| **Office of the Secretary of Health and Human Services** | | | | | |
| COVID-Biomedical Advanced Research and Development Authority (BARDA) | 93.U10 | Duke University | HHSO100201400002I | (64) | - |
| **Substance Abuse and Mental Health Services Administration** | | | | | |
| Substance Abuse and Mental Health Services_Projects of Regional and National Significance | 93.243 | | | 177,849 | - |
| Substance Abuse and Mental Health Services_Projects of Regional and National Significance | 93.243 | Vision for Children at Risk | VCRSTLPL | 114,158 | - |
| Congressional Directives | 93.493 | BJC Health System | 6H79FG000822-01M004 | 20,070 | - |
| State Targeted Response to the Opioid Crisis Grants | 93.788 | University of Missouri, St. Louis | 1H79TI085748-01 | 228,602 | - |
| **TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES** | | | | 6,585,658 | 717,687 |
| **DEPARTMENT OF JUSTICE** | | | | | |
| **Office of Juvenile Justice and Delinquency Prevention** | | | | | |
| Second Chance Act Reentry Initiative | 16.812 | Soulfisher Ministry | 15BJA-22-GG-01773-SCAX | 64,915 | |
| Second Chance Act Reentry Initiative | 16.812 | Soulfisher Ministry | 15RBJA-22-GG-04605-SCAX | 134,617 | - |
| | | | | 199,532 | - |
| **DEPARTMENT OF HOMELAND SECURITY** | | | | | |
| Disaster Grants - Public Assistance (Presidentially Declared Disasters) | 97.036 | | | 1,329,297 | - |

The accompanying notes are an integral part of this schedule

# Washington University
# Schedule of Expenditures of Federal Awards
# For the Year Ended June 30, 2024

| Cluster Title/Federal Grantor/Program Title | Assistance Listing Number | Pass Through Entity | Pass-through Entity Identification Number | Total Expenditures | Passed to Sub-Recipients |
|---|---|---|---|---|---|
| **DEPARTMENT OF STATE** | | | | | |
| International Programs to Combat Human Trafficking | 19.019 | University Of Georgia | SSJTIP22CA0029 | 113,130 | - |
| AEECA/ESF PD Programs | 19.900 | American Councils for International Education | SUZ80021CA3148 | 6,294 | - |
| | | | | 119,424 | - |
| **DEPARTMENT OF THE TREASURY** | | | | | |
| **Internal Revenue Service** | | | | | |
| Low Income Taxpayer Clinics | 21.008 | | | 208,736 | - |
| **DEPARTMENT OF VETERANS AFFAIRS** | | | | | |
| Department of Veterans Affairs | 64.RD | | | 11,564 | - |
| **NATIONAL ARCHIVES AND RECORDS ADMINISTRATION** | | | | | |
| **NATIONAL ENDOWMENT FOR THE ARTS** | | | | | |
| Promotion of the Arts Grants to Organizations and Individuals | 45.024 | | | 2,154 | - |
| **Total Other Sponsored Programs from Other Federal Agencies** | | | | 1,870,707 | - |
| **Total Other Sponsored Programs** | | | | 8,544,669 | 717,687 |
| **Student Financial Assistance Cluster** | | | | | |
| **DEPARTMENT OF EDUCATION** | | | | | |
| Federal Supplemental Educational Opportunity Grant | 84.007 | | | 1,516,651 | - |
| Federal Work-Study Program | 84.033 | | | 1,945,088 | - |
| Federal Pell Grant Program | 84.063 | | | 8,365,352 | - |
| Teacher Education Assistance for College and Higher Education Grants | 84.379 | | | 124,476 | - |
| Education Stabilization Fund | 84.425 | | | 9,406 | - |
| **Federal Direct Student Loans** | | | | | |
| New Loans Issued during 2024 | 84.268 | | | 60,199,706 | - |
| **Federal Perkins Loans** | | | | | |
| Outstanding Loans as of July 1, 2023 | 84.038 | | | 7,026,348 | - |
| **Total Student Financial Assistance Cluster** | | | | 79,187,027 | - |
| **Highway Safety Cluster** | | | | | |
| **DEPARTMENT OF TRANSPORTATION** | | | | | |
| Police Traffic Services | 20.600 | Missouri Dept of Transportation | 23DL02001 | 39,868 | - |
| **Food for Peace Cluster** | | | | | |
| **AGENCY FOR INTERNATIONAL DEVELOPMENT** | | | | | |
| Food for Peace Development Assistance Program (DAP) | 98.007 | Catholic Relief Services | 720BHA21RFA00002 | 353,039 | - |
| **TRIO Cluster** | | | | | |
| **DEPARTMENT OF EDUCATION** | | | | | |
| TRIO - Student Support Services | 84.042 | | | 350,935 | - |
| **Total Federal Award Expenditures** | | | | $ 930,473,889 | $ 103,525,507 |

The accompanying notes are an integral part of this schedule

## 1. Summary of Significant Accounting Policies

### Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the expenditures of Washington University (the "university") under programs of the Federal Government for the year ended June 30, 2024. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the financial statements. The university includes the amounts in the Schedule in net assets without donor restrictions of the university's Consolidated Statement of Activities for the year ended June 30, 2024.

The Schedule is prepared on the accrual basis of accounting. Assistance Listing and pass-through numbers are provided when available. Negative amounts presented as expenditures represent subsequent period adjustments, transfers, or vendor credits. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

### Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

## 2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 26.0% to 55.5%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2024.

## 3. Federal Student Loan Programs

The following schedule includes the Student Financial Aid (SFA) loan balances outstanding as of June 30, 2024:

| Student Financial Aid | Federal Assistance Listing Number | Outstanding Balances |
|---|---|---|
| **U.S. Department of Education** | | |
| Federal Perkins Loan Program | 84.038 | 4,589,887 |

# Reports on Compliance and on Internal Controls

**Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards***

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards,* issued by the Comptroller General of the United States, the consolidated financial statements of Washington University and its subsidiaries (the "University), which comprise the consolidated statement of financial position as of June 30, 2024, and the related consolidated statements of activities and of cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated September 27, 2024.

**Report on Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University 's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

**Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.

**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Washington, District of Columbia

September 27, 2024

**Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance**

To the Board of Trustees of Washington University

**Report on Compliance for Each Major Federal Program**

***Opinion on Each Major Federal Program***

We have audited Washington University's (the "University") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2024. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2024.

***Basis for Opinion on Each Major Federal Program***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

***Auditors' Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform

Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

***Other Matters***

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 11 "Gramm-Leach-Bliley Act-Student Information Security." This section includes two suggested audit procedures with respect to verification that the institution (1) designated a Qualified Individual responsible for implementing and monitoring the institution's information security program, and (2) has a written information security program that addresses the remaining six required minimum elements that are detailed in the OMB Compliance Supplement, Part Five, Student Financial Assistance Cluster, Special Tests and Provisions, item 11, Gramm-Leach-Bliley Act – Student Information Security. Our procedures in relation to these two items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these two items. Our procedures did not include an analysis of the adequacy or completeness of the minimum required elements of the institution's information security program.

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2024-001, 2024-002, and

2024-003. Our opinion on each major federal program is not modified with respect to these matters.

*Government Auditing Standards* requires the auditor to perform limited procedures on the University's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs and corrective action plan. The University's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

**Report on Internal Control Over Compliance**

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Washington, District of Columbia

March 7, 2025

# Schedule of Findings and Questioned Costs

# Washington University
## EIN# 43-0653611
## Schedule of Findings and Questioned Costs
## For the Year Ended June 30, 2024

**Part I - Summary of Auditor's Results**

**Financial Statements**

| | | | | |
|---|---|---|---|---|
| Type of auditor's report issued: | Unmodified | | | |
| Internal control over financial reporting: | | | | |
| Material weakness (es) identified? | ____ | Yes | __X__ | No |
| Significant deficiency (ies) identified not considered to be material weaknesses? | ____ | Yes | __X__ | None reported |
| Noncompliance material to financial statements noted? | ____ | Yes | __X__ | No |

**Federal Awards**

| | | | | |
|---|---|---|---|---|
| Type of auditor's report issued on compliance for major programs: | Unmodified | | | |
| Internal control over major programs: | | | | |
| Material weakness (es) identified? | ____ | Yes | __X__ | No |
| Significant deficiency (ies) identified not considered to be material weaknesses? | ____ | Yes | __X__ | None reported |
| Any audit findings disclosed that are required to be reported in accordance with Uniform Guidance Section 200.516(a)? | __X__ | Yes | ____ | No |

**Identification of Major Programs**:

| Assistance Listing Number(s) | Name of Federal Program or Cluster |
|---|---|
| Various | Research and Development Cluster |
| Various | Student Financial Aid Cluster |
| 97.036 | Disaster Grants - Public Assistance (Presidentially Declared Disasters) |

| | | | | |
|---|---|---|---|---|
| Dollar threshold used to distinguish between Type A and Type B programs: | $3,000,000 | | | |
| Auditee qualified as low-risk auditee? | __X__ | Yes | ____ | No |

# Washington University
## EIN# 43-0653611
## Schedule of Findings and Questioned Costs
## For the Year Ended June 30, 2024

**Part II – Financial Statement Findings**

There are no financial statement findings to report.

**Part III – Federal Award Findings and Questioned Cost**

**Finding 2024-001: Special Tests and Provisions –Disbursements to or on Behalf of Students, Enrollment Reporting, and Return of Title IV funds**

**Grantor:** Department of Education
**Program:** Student Financial Assistance Cluster
**Assistance Listing#:** 84.007, 84.033, 84.063 & 84.268
**Title:** Federal Supplemental Educational Opportunity Grants, Federal Work-Study Program, Federal Pell Grant Program, Federal Direct Student Loans
**Award Year:** 07/1/2023 – 06/30/2024
**Award Number:** N/A

**Criteria**
34 CFR 668.165 which requires the institution to obtain the student's voluntary consent to participate in electronic transactions.

34 CFR 668.41 which notes an institution annually must distribute to all enrolled students a notice of the availability of the information required to be disclosed under the notification requirements of the Family Educational Rights and Privacy Act of 1974.

34 CFR 668.165 which requires the institution, in advance of disbursement, to provide a general notification to all students receiving Title IV program funds including (1) amount of funds the student can expect to receive from each Federal Student Aid (FSA) program and (2) how and when those funds will be disbursed

34 CFR Section 674.19 which states unless it expects to submit its next updated enrollment report to the Secretary within the next 60 days, an institution must notify the Secretary within 30 days after the date the school discovers that a student has ceased to be enrolled on at least a half-time basis or failed to enroll on at least a half-time basis for the period for which the loan was intended. Student status changes are required to be reported at both the "Campus Level" and "Program-Level" as each have separate record types.

34 CFR 668.21-22 which includes the requirements for determining the amount of Title IV funding to be returned to the Department of Education as well as the required order and timeframe for return of Title IV funds.

**Condition**

Disbursements to or on behalf of students

- For 21 of 25 students sampled, the University was unable to provide evidence of each student's affirmative consent for electronic communications
- For 25 of 25 students sampled, the University was unable to provide evidence that each student received notification of the availability of the Annual Security Report and Annual Fire Safety Report as required under the Clery Act
- For 1 of 25 students sampled, the University was unable to evidence that they provided the student with their general award notification which includes the amount of funds expected to be received and timing of disbursement

Enrollment reporting

- For 1 of 25 students sampled, the student's change in enrollment status was not reported to the National Student Loan Data System (NSLDS) within the 60 required timeframe

Return of Title IV funds

- For 1 of 6 students sampled, the University did not complete a return of Title IV funding worksheet to determine whether financial aid funding was required to be returned to the Department of Education

**Cause**
The University experienced turnover in the Student Financial Aid Office as well as other offices that support the University's ongoing compliance with the Student Financial Assistance regulations. Additionally, the absence of a secondary level of review impacted the University's ability to ensure compliance with federal regulations.

**Effect**
The University's was unable to demonstrate compliance with certain required federal regulations.

**Questioned Costs**
There are no questioned costs associated with this finding as the finding primarily relates to required student notifications and reporting. As it specifically relates to the Return of Title IV funds exception, no questioned costs were noted as there were no amounts that were required to be returned to the Department of Education.

**Recommendation**
Management should cross train individuals within the Student Financial Aid Office as well as other offices that support financial aid administration to ensure the University is able to remain compliant with federal regulations during periods of turnover in personnel. Separately, the University should implement a process for reminders, secondary review, and follow up to ensure reporting obligations are met timely, completely, and accurately.

**Management's View and Corrective Action Plan**
Please refer to management's views and corrective action plan.

**Finding 2024-002: Reporting - Schedule of Expenditures of Federal Awards**

**Grantor:** National Institute of Health
**Program:** Research and Development
**Assistance Listing#:** 93.352
**Title:** A Washington University Gnotobiotic Research, Education and Transgenic center for modeling genetic and environmental effectors of disease pathogenesis
**Award Year:** 09/20/2019 – 05/31/2024
**Award Number:** 1C06OD02830601

**Criteria**
2 CFR 200.510 which requires the auditee to prepare a Schedule of Expenditures of Federal Awards (SEFA) for the period covered by the auditee's financial statements that includes the total federal awards expended.

**Condition**
Expenditures totaling $2,013,944 related to a construction grant were incurred in prior fiscal years but recorded in the SEFA during the current fiscal year.

**Cause**
The management of the construction grant activity resided in a department other than Sponsored Projects Accounting. Therefore, the grant was excluded from the normal processes for capturing activity in the SEFA.

**Effect**
The current year SEFA is overstated by amounts that should have been recorded in the SEFA in prior years.

**Questioned Costs**
There are no questioned costs as amounts sampled from the expenditures recorded in the current year SEFA were deemed allowable.

**Recommendation**
Management should enhance its coordination and review procedures for special purpose grants managed outside of Sponsored Projects Accounting to ensure that amounts associated with such grants are completely and accurately reported in the SEFA.

**Management's View and Corrective Action Plan**
Please refer to management's views and corrective action plan.

**Finding 2024-003: Procurement, Suspension, and Debarment**

**Grantor:** National Institute of Health
**Program:** Research and Development
**Assistance Listing#:** 93.395, 93.866
**Title:** Cancer Treatment Research, Aging Research
**Award Year:** 03/01/2019-11/30/2023, 02/15/2021-01/31/2026
**Award Number:** 3UM1CA18670405S1, 5R01AG07094105

**Criteria**
2 CFR 200, Subpart D which require institutions to:

- Maintain and use documented procedures for procurement transactions under a federal award or subaward, including for acquisition of property or services
- Maintain records sufficient to detail the history of each procurement transaction. These records must include the rationale for the procurement method, contract type selection, contractor selection or rejection, and the basis for the contract price

2 CFR 200.214 which restricts making federal awards, subawards, and contracts with certain parties that are debarred, suspended, or otherwise excluded from receiving or participating in federal awards.

**Condition**

- For 2 of 25 procurements sampled, the University documented both supplier justification and the purchase order after receipt of an invoice from the vendor
- For 1 of 25 procurements sampled, the University did not maintain evidence of their price/cost analysis as required when the procurement exceeds the simplified acquisition threshold of $250,000
- For 1 of 25 samples selected for suspension and debarment, the University performed the suspension/debarment screen after the date and payment of the vendor invoice

**Cause**
For vendors that existed in the legacy accounting system, the University has not consistently documented vendor screening results. Additionally, procurement decisions/conclusions were not consistently documented prior to executing transactions with vendors.

**Effect**
There is a risk that the University could enter into transactions with vendors that are suspended/debarred. Separately, failure to document procurement decisions in a timely manner could impact the University's ability to demonstrate compliance with federal regulations and the University's procurement policies.

**Questioned Costs**
There are no questioned costs as the vendor selected was not suspended or debarred and procurement transactions were deemed allowable.

**Recommendation**
Management should enhance its existing processes to ensure all decisions and conclusions supporting procurements are made in a timely manner and completely documented in the procurement files prior to entering into transactions with vendors. The University should also ensure that all required suspension and debarment checks are performed, and documentation is maintained in advance of transacting with vendors.

**Management's View and Corrective Action Plan**
Please refer to management's views and corrective action plan.

# Management's Views and Corrective Action Plan

# Washington University
## EIN# 43-0653611
## Management's Views and Corrective Action Plan
## For the Year Ended June 30, 2024

**Accountant's Finding 2024-001: Special Tests and Provisions –Disbursements to or on Behalf of Students, Enrollment Reporting, and Return of Title IV funds**

Management concurs with the finding and is implementing the following corrective actions:

Disbursements to or on behalf of students

- Student Financial Services (SFS) has updated the Financial Assistance Terms and Conditions, which is required to be certified annually by all students receiving aid, to include consent to receive electronic communications.
- In accordance with the requirements of the Clery Act, the Annual Campus Security and Fire Safety Report (ASFSR) is posted and available on the WU Police Department website. The WU Police Department has partnered with the Office of the Executive Vice Chancellor for Administration and the Office of Information Technology to establish responsibilities and timelines that will ensure students, faculty, and staff are notified, prior to October 1 of each year, that the most recent ASFSR is available on the website. Additionally, the university's Internal Audit Department will follow-up quarterly to ensure implementation of this action plan.
- Student award notifications are delivered to students electronically through an automated process that identifies aid awarded but not yet disbursed. For the rare occasions that a student may have aid awarded and disbursed in the same day, therefore bypassing the overnight award notification process, SFS has implemented the review of a pre-disbursement daily report to identify students who have an aid offer but were not provided an aid notification.

Enrollment reporting

- The Office of the Registrar has updated its procedures to include off-schedule enrollment submissions through NSLDS. On the completion of the National Student Clearinghouse graduate-only file and corrections, an ad-hoc enrollment submission request will be completed.

Return of Title IV funds

- To ensure compliance with its internal policy, SFS has updated procedures to complete a formal R2T4 calculation within the student aid system on all withdrawing Title IV students. To monitor that no students are missed as part of the routine procedures, a new report has been created to identify withdrawn Title IV students. This report will be compared bi-weekly to the student aid system to confirm that R2T4 calculations have been completed.

Additional

- SFS depends on multiple departments across campus to compliantly deliver federal Title IV aid. SFS will develop an annual training plan for campus partners to ensure they have the knowledge and resources to administer federal aid in compliance with federal regulations. SFS has hired an Associate Director of Operations and Training who will develop this training during calendar year 2025. The university's Internal Audit Department will follow-up quarterly to ensure implementation of this action plan.

**Completion Date:** June 30, 2025

**University Contact and Responsible Party**: Michael Runiewicz, Assistant Vice Provost & Director of Student Financial Services, (314) 935-5900

# Washington University
## EIN# 43-0653611
## Management's Views and Corrective Action Plan
## For the Year Ended June 30, 2024

**Finding 2024-002: Reporting - Schedule of Expenditures of Federal Awards**

Management concurs with the finding and will ensure that construction grant expenditures are recorded in the financial system in the proper period by documenting appropriate procedures in coordination between Sponsored Projects Accounting office and the Property Accounting Office.

**Completion Date:** December 31, 2025

**University Contact and Responsible Party**: Krystina J. Gross, Associate Vice Chancellor for Finance and Sponsored Projects, (314) 935-2073

# Washington University
## EIN# 43-0653611
## Management's Views and Corrective Action Plan
## For the Year Ended June 30, 2024

**Finding 2024-003: Procurement, Suspension, and Debarment**

Management will review and clarify our procurement policies and procedures to ensure alignment with Uniform Guidance. We will clarify what documentation is sufficient to justify a lack of competition for purchases greater than the micro-purchase threshold. We will reinforce the need to document procurement decisions prior to entering into the procurement process and adequately retain the documentation by issuing targeted communication and presenting at various standing research administration staff meetings.

**Completion Date:** December 31, 2025

**University Contact and Responsible Party**: Krystina J. Gross, Associate Vice Chancellor for Finance and Sponsored Projects, (314) 935-2073

# Summary of Status of Prior Audit Findings

# Washington University
## Summary of Status of Prior Audit Findings
## Year Ended June 30, 2024

**Part IV – Federal Award Findings**

**Finding 2023-001 Allowable Costs/Cost Principles – Cost Transfers**

During fiscal year 2023, 44 cost transfers, which included cost transfers related to payroll and non-payroll costs, were selected for testing. 25 selections from the Research and Development cluster totaled $368,956, and 19 selections from the Sickle Cell Treatment Demonstration Program cluster totaled $28,628. Two of the 25 Research and Development cluster cost transfers, totaling $24,438, were not completed within 90 days following the discovery of error occurrence as required by the National Institute of Health's (NIH) Grants policy. One of the 19 Sickle Cell Treatment Demonstration Program cluster cost transfers, totaling $4,951, was not completed within 90 days following the error occurrence as required by the Department of Health and Human Services (DHHS) Grants policy.

**Status and Action Taken:**

Management has implemented various appropriate corrective actions. The University's Cost Transfer for Sponsored Projects policy was updated during fiscal year 2024 to include more specific language regarding the timing requirements for awards from NIH, DHHS, and other sponsoring agencies (see below). In addition, management continues to provide ongoing communication to the research community about the importance of adhering to cost transfer deadlines through its various communication channels, including, but not limited to, Research Administrator meetings and the Research News emails.

Update to Cost Transfer for Sponsored Projects policy:

Faculty and staff are responsible for ensuring that Cost Transfers are processed in a timely manner. Cost Transfers should be prepared and submitted within 90 days from the date of discovery (per National Institutes of Health Grants Policy Statement section 7.5). In cases when the sponsor's (federal or non-federal) terms and conditions relating to the timing of Cost Transfers are stricter than this policy, the sponsor's terms and conditions are applicable and supersede this policy. Note: The Department of Health and Human Services agencies (e.g., funding from HRSA, CDC, AHRQ…) grants policy requires cost transfers to be made promptly after the error occurs but no later than 90 days following occurrence unless a longer period is approved in advance by the GMO.